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Abbreviations
AAS Atomic absorption spectrometry
8-AG 8-azaguanine
AV Adsorptive voltammetry
CHO Chinese hamster ovary
EPA US Environmental Protection Agency
FAAS Flame atomic absorption spectrometry
FEF25  Forced expiratory flow at 25% of vital capacity
FEV0.5 Forced expiratory volume in 0.5 second
FEV1 Forced expiratory volume in one second
FVC Forced vital capacity
GFAAS Graphite furnace atomic absorption spectrometry
HGPRT Hypoxanthine-guanine phosphoribosyl transferase
HSE UK Health and Safety Executive
I50 Concentration required to produce a 50% inhibition
ICP-AES Inductively coupled plasma atomic emission spectrometry
ICP-MS Inductively coupled plasma mass spectrometry
IgE Immunoglobulin E
IPCS International programme on chemical safety
LC50 Inhalation concentration that is estimated to be lethal to 50% of test 
animals
LD1 Dose that is estimated to be lethal to 1% of test animals
LD25 Dose that is estimated to be lethal to 25% of test animals
LD50 Dose that is estimated to be lethal to 50% of test animals
LOAEL Lowest observed adverse effect level
MMAD Mass mean aerodynamic diameters
NIOSH US National Institute for Occupational Safety and Health
NOAEL No observed adverse effect level
OEL Occupational exposure limit
OSHA US Occupational Safety and Health Administration
OVA Ovalbumin
PCA Passive cutaneous anaphylaxis
PCE Polychromatic erythrocyte
PLN Popliteal lymph node
ppm Parts per million (in air or in diet)
RAST Radioallergosorbent test
RL Pulmonary flow resistance
SHE Syrian hamster embryo
TWA Time-weighted average
11. Introduction
The use of platinum has increased worldwide during the last 20 years. Large
amounts of platinum are used e.g. in the chemical and petroleum industry, but the
increased demand for platinum mainly is dependent on the introduction of the auto-
mobile catalytic converter systems. In this document relevant studies concerning
platinum metal and various platinum compounds have been reviewed, but studies
on the anticancer drug cisplatin and analogues usually have been excluded. The
possibility to draw general conclusions on platinum toxicity, relevant for the work
environment, from data on cisplatin is limited. The handling of cisplatin and its
analogues e.g. by pharmacy and hospital personnel is a special case of possible
occupational exposure. In most Nordic countries instructions for handling cytostatic
drugs are available. Furthermore, a summary of current knowledge of chemical
health risks (including cytostatics) for health care personnel in the Nordic countries
has been published recently (163).
2. Chemical identification
Chemical formula, molecular weight and CAS numbers of some platinum com-
pounds are listed in Table 1.
3. Physical and chemical properties
Platinum is a relatively soft and ductile, silvery metal with the atomic number 78
and belonging to group VIII of the periodic system (12). Platinum occurs mainly as
the isotopes 194Pt (32.8%), 195Pt (33.7%) and 196Pt (25.4%) (108). Platinum is
relatively inert, with respect to chemical attack by oxygen or many acids, but the
chemical reactivity is markedly influenced by the state of subdivision of the metal
(108). Platinum does not visually exhibit an oxide film when heated, although a thin
adherent film forms below 450°C. Above this temperature platinum slowly loses
weight because of the formation of the volatile oxide (PtO2) (2). Platinum metal can
be affected by halogens, cyanides, sulfur, molten sulfur compounds, heavy metals,
and hydroxides (63). It can form alloys and its tendency to form complexes is
strong (60, 120). The principal oxidation states of platinum are +2, +4 and 0; of
these, the first is the most common (108). The highest oxidation state of the element
is +6 (platinum hexafluoride) (46, 90).
Platinum binds to a large number of ligands (ions or neutral molecules), some of
which have more than one binding site, to form neutral or charged complexes or
salts. The divalent compounds are predominantly four-coordinate and square
planar, the tetravalent compounds six-coordinate and octahedral and the zerovalent
compounds four-coordinate and tetrahedral (22, 46). Halogen- and nitrogen-donor
2Table 1. Chemical identification of some platinum compounds
Chemical name
(Synonyms)
Chemical formula Molecular weight CAS number
Platinum (platin, platinum
metal, platinum black,
platinum sponge, liquid
bright platinum)
Pt 195.09 7440-06-4
Platinum(II) oxide
(platinous oxide, platinum
monooxide)
PtO 211.08 12035-82-4
Platinum(IV) oxide,
(platinic oxide, platinum
dioxide)
PtO2 227.08 1314-15-4
Platinum(II) sulphide PtS 227.15 12038-20-9
Platinum(IV) sulphide PtS2 259.21 12038-21-0
Platinum(II) chloride
(platinous chloride,
platinous dichloride,
platinum dichloride)
PtCl2 265.99 10025-65-7
Platinum(IV) chloride
(platinum tetrachloride,
tetrachloroplatinum)
PtCl4 336.89 37773-49-2
(pentahydrate:
13454-96-1)
Hexachloroplatinic(IV) acid
(chloroplatinic acid, platinic
acid, dihydrogen hexa-
chloroplatinate, hydrogen
hexachloroplatinate)
H2PtCl6 409.81 16941-12-1
(hexahydrate:
18497-13-7)
Ammonium tetrachloro-
platinate(II) (ammonium
chloroplatinite, diammo-
nium tetrachloroplatinate,
platinous ammonium
chloride)
(NH4)2PtCl4 372.97 13820-41-2
Ammonium hexachloro-
platinate(IV) (diammonium
hexachloroplatinate, platinic
ammonium chloride)
(NH4)2PtCl6 443.87 16919-58-7
Potassium tetrachloro-
platinate(II) (potassium
chloroplatinite, dipotassium
tetrachloroplatinate, plati-
nous potassium chloride)
K2PtCl4 415.09 10025-99-7
3Table 1. Cont.
Chemical name
(Synonyms)
Chemical formula Molecular weight CAS number
Potassium hexachloro-
platinate(IV) (dipotassium
hexachloroplatinate, platinic
potassium chloride)
K2PtCl6 485.99 16921-30-5
Sodium hexachloro-
platinate(IV) (disodium
hexachloroplatinate, sodium
platinum chloride)
Na2PtCl6 453.77 16923-58-3
*derived from RTECS data lists 1996; Registry file STN 1996; Ref. 56, 82).
ligands are common, but in the divalent oxidation state platinum readily form
complexes with ligands containing donor atoms from most groups of the periodic
Table (46). Several of these chemicals exist as cis and trans isomers and the
geometric arrangement is of great importance in biochemical processes (63, 73,
166, 178).
The compounds vary in colour from yellow (e.g. ammonium hexachloroplatinate
(IV), platinum sulphate), to olive-green (e.g. platinum(II) chloride), to red/red-
brown (e.g. ammonium tetrachloroplatinate(II), platinum(IV) chloride), and to
black or almost black (platinum(II) sulphide, platinum(IV) sulphide, platinum(IV)
oxide) (2, 12, 82, 90, 154, 172). The solubility in water also differs between plati-
num compounds (154). Platinum metal and platinum oxides are insoluble, while
e.g. the complex salts ammonium hexachloroplatinate(IV) and potassium hexa-
chloroplatinate(IV) are sparingly soluble in water. The tetrachloroplatinates
ammonium tetrachloroplatinate(II) and potassium tetrachloroplatinate(II) are more
easily soluble than the corresponding hexachloroplatinates. Some constants of
platinum and various platinum compounds are given in Table 2.
4. Occurrence, production and use
4.1. Occurrence
Platinum is a widely distributed but rare metal composing about 5x10-7% of the
earth«s crust (3). In its native state, platinum generally is alloyed e.g. with small
amounts of the other platinum metals or with iron and occurs as a blend of fine
grains or nuggets in alluvial deposits in Russia, Alaska and Columbia. The econo-
mically significant sources of platinum metal are in Russia, South Africa and
Canada, where it can be found in small quantities in nickel and copper ores (59,
108, 120). The principal minerals containing platinum are sperrylite (PtAs2),
cooperite (Pt,Pd)S and braggite (Pt,Pd,Ni)S (90).
4Table 2. Some chemical and physical data* for platinum and some platinum
compounds
Chemical Melting Boiling Density Solubility
name point point (g/cm3) in water
Platinum 1768°C 3825°C 21.45 (20°C) insoluble
Platinum(II) oxide 325°C decomp - 14.1 insoluble
Platinum(IV) oxide 450°C - 11.8 insoluble
Platinum(II) sulphide - - 10.25 insoluble
Platinum(IV) sulphide 225-250°C decomp - 7.85 insoluble
Platinum(II) chloride 581°C decomp - 6.0 insoluble
Platinum(IV) chloride 327°C decomp - 4.30 slightly soluble
Platinum(IV) chloride
(pentahydrate)
- - 2.43 soluble
Platinum(IV) sulphate
(tetrahydrate)
- - - soluble
Hexachloroplatinic(IV)
acid (hexahydrate)
60°C - 2.43 very soluble
Ammonium tetra-
chloroplatinate(II)
decomp - 2.94 soluble
Ammonium hexa-
chloroplatinate(IV)
380°C decomp - 3.07 slightly soluble
Potassium tetrachloro-
platinate(II)
500°C decomp - 3.38 soluble
Potassium hexachloro-
platinate(IV)
250°C decomp - 3.50 slightly soluble
Sodium hexachloro-
platinate (IV)
250°C decomp - 3.5 very soluble
(hexahydrate)
*derived from 12,56,82,154,172.
The occurrence of platinum in ambient air before the introduction of cars with
catalytic converters was mainly dependent on the concentration in nature (e.g. in
soil particles, fertilizers) (3). When platinum concentrations in road dusts were
analysed in Sweden in 1984 and 1991 a significant increase in platinum concentra-
tion was found in all fractions in 1991 (174). Few measurements of platinum in
ambient air have been reported. The levels of platinum in air samples taken near a
freeway in California in 1974 (when few car catalysts were used) were below the
5detection  limit of 0.05 pg/m3 (67). Mean concentration of platinum in 1973 near a
highway outside the city of Ghent (Belgium) was reported in another study (146) to
be less than 10 pg/m3. In Germany, platinum air concentrations were measured
close to city roads in 1989 and found to be up to 13 pg/m3. In rural areas the
concentrations were at most 1.8 pg/m3 (Tlg & Alt, 1990 cited in 63). At that time
few German cars were equipped with catalysts and thus these levels could reflect
background levels. The platinum emission from the monolith-type catalysts used in
Europe has been calculated to be 2 ng/km travelled at a speed of 60 km/h and about
40 ng/km at a speed of 140 km/h (78). Based on dispersion models used by  US
EPA and assuming an average emission rate of approximately 20 ng/km, the
ambient air concentrations of total platinum near or on roads were calculated to be
up to 0.09 ng/m3 (the highest values in a roadway tunnel) (63, 78). In a more recent
study (3) air levels of 0.3 to 30 pg Pt/m3 were measured in Germany. The chemical
nature of the platinum emissions has not been fully determined, but in the case of
the first-generation pellet-type catalyst used in the USA, only 10% of the platinum
emitted was water-soluble (134, 135). At temperatures above 500°C (as in the
exhaust converter) metallic platinum reacts with oxygen to form platinum(IV)oxide
(8, 134). According to an evaluation made by IPCS, it is not possible to conclude if
microorganisms in the environment are able to biomethylate platinum compounds.
For further details on the occurrence of platinum in the environment see references 3
and 63.
When platinum levels in blood, hair and urine were measured in Australia no sig-
nificant difference in the Pt concentration between residents in high or medium pol-
luted or unpolluted areas was found (113, 168). The concentrations of total
platinum in a range of foodstuffs from Sydney (prepared by normally used cooking
methods) also was determined (168). The levels of platinum were between 8.11
mg/kg (liver) and 0.13 mg/kg (full-cream milk). Food-groups containing high levels
of platinum were meat (0.7-5.7 mg/kg; mean 3.2) and grain products (0.6-5 mg/kg;
mean 3.2). Eggs also contained high levels of platinum (about 3.5 mg/kg), whereas
low levels of platinum were found in fruit and vegetables (0.2-2.1 mg/kg; mean
0.82) and dairy foods (mean 0.27 mg/kg). Calculations based on these values
showed the large contribution of the diet to the Pt levels in humans. The total dietary
intake of Pt for an adult Australian was calculated to be about 1.4 mg/day (female:
1.15 mg/day; male: 1.73 mg/day) (168). However, when the baseline levels of
platinum e.g. in blood were determined by these authors the obtained values were
very high compared to the values obtained by other researchers. Thus, the reliability
of the platinum levels in food might be questioned too. In an older study from
United Kingdom a total daily intake of less than 1 mg platinum was estimated, based
on an analysis of a diet sample, but no data were given on the platinum content of
the foods analysed (43).
4.2. Production
Platinum is obtained from mined ore and recycled metal (58). The ore is concentra-
ted following flotation and smelting operations, and individual metals are separated
6and refined by a complex chemical treatment. During the refining the concentrate is
dissolved in aqua regia or hydrochloric acid/ chlorine. Hexachloroplatinic(IV) acid
or sodium hexachloroplatinate(IV) (after treatment with sodium chloride) is formed
and in both cases addition of ammonium chloride leads to formation of ammonium
hexachloroplatinate(IV) (yellow salt) (58, 63, 120, 138). After calcination at
600-700°C a crude platinum metal sponge is formed, which undergoes further
refining. Finally, after heating up to 1000°C a grey metal sponge of platinum
>99.9% pure is produced (46, 58, 120). There are other methods of purification:
e.g. platinum can be reduced to the metal from aqueous solution of its salts,
whereby a black powder of platinum metal (platinum black) is produced (12, 60,
63). Platinum and its alloys are manufactured e.g. into sheet, wire, and foil for use
in jewellery, dentistry, and in the electrical and chemical industries (59, 90). Hexa-
chloroplatinic(IV) acid, the most important  platinum compound (formed when
platinum is dissolved in aqua regia), is isolated as the hydrate and is the source of
many other platinum compounds (12, 108).
Intensive studies have been made to find useful anticancer drugs similar to cis-
platin and over two thousand analogues have been synthesized and tested for anti-
tumor activity (132).
4.3. Use
The use of platinum metal and its alloys in industry is mainly related to their extra-
ordinary catalytic properties. As a catalyst platinum is used in hydrogenation,
dehydrogenation, isomerization, cyclization, dehydration, dehalogenation, and oxi-
dation reactions (12, 90). One of its major industrial uses is in the oil industry. The
metal is dispersed on small pellets of alumina or silica-alumina and used to upgrade
the octane rating of gasoline (12, 108). In the chemical industry platinum-rhodium
alloys are used in catalyst gauzes for ammonia oxidation during the production of
nitric acid. Platinum catalysts may also be used e.g. in a process for making sulfuric
acid (12, 108). Ceramic honeycomb materials impregnated with platinum are used
in industry for exhaust-gas control (108). Platinum-rhodium or platinum-palladium
catalysts are used to control emissions from automobile exhausts and oxidizes
carbon monoxide and unburnt hydrocarbons and in the case of Pt-Rh reduces
nitrogen oxides (22, 63).
Resistance to many forms of corrosion and strength at high temperatures are other
important properties of platinum and it is often alloyed with other platinum metals or
base metals and used in electric contacts, circuits printed onto ceramic substrates (in
the electronics industry), laboratory and plant apparatus, electrochemical anodes,
spinnerets used for synthetic fiber extrusion, bushings for the production of fiber-
glass and vessels used for example in glass-making industry.  Platinum is also used
to produce a silvery lustre on ceramic glazes (12, 22, 63, 90, 108). Some alloys
containing platinum are used in dentistry and in surgical tools and implants. Another
well-known use of platinum and its alloys are in jewellery (12, 63).
Platinum salts may be used e.g. in the manufacture of platinum catalysts, for
electroplating, and for photographic applications. Hexachloroplatinic(IV) acid may
7be used in platinizing alumina or charcoal in catalyst production (59, 63). A number
of salts can be used in the electrodeposition of platinum. Industrial items (e.g. avia-
tion components, electrodes, turbine blades, wire), as well as jewellery and decora-
tive items may be electroplated with platinum. Established processes are based on
materials such as diamminedinitroplatinum(II), sodium hexahydroxyplatinate(IV),
potassium hexahydroxyplatinate(IV), hexahydroxyplatinic acid(IV), hexachloro-
platinic(IV) acid or dinitrosulphatoplatinous(II) acid (potassium dinitrosulphato-
platinate(II), potassium dinitrodichloroplatinate(II) or potassium trinitrochloro-
platinate(II) are used for making up solutions), but electrolytes based on chlorides
(basic salts: platinum(IV) chloride, ammonium hexachloroplatinate(IV), hexachloro-
platinic(IV) acid) have no great significance today. New series of aqueous platinum
electroplating baths based on tetraammineplatinum(II) compounds are developing
(10, 150). Potassium tetrachloroplatinate(II) (used as a toner in the developing of
photographic paper) and potassium hexachloroplatinate(IV) are soluble platinum
salts used in the photographic industry (59, 90, 180). Potassium tetrachloro-
platinate(II) possibly also may be used as a dental drug (dentine desensitizer) (72).
Certain platinum complexes, like cisplatin and its analogues are used as anticancer
drugs.
The demand for platinum has increased worldwide during the last twenty years
mainly because of the introduction of the automobile exhaust gas catalysts (Table
3). Before that most of the platinum was used as catalysts in the chemical and pet-
roleum industry. In Sweden the largest amounts of platinum still are used in the
petroleum industry (Table 4). According to Statistics Sweden (SCB) at least
2-2.5Êtons of platinum (for different purposes) was imported in Sweden in 1993.
Secondary sources of platinum may come from recycling of used equipment. In
Norway 151 kg of platinum (rough, semi-manufacture, pulverous) was imported
and 1921 kg was exported in 1994 (Statistics Norway).
Platinum and some inorganic platinum compounds are used in Sweden for
naphtha-reforming to upgrade the octane rating of gasoline and during the produc-
tion of organic base chemicals (e.g. for cleaning of gases) (Tables 4 and 5). A solu-
tion of hexachloroplatinic(IV) acid and rhodium chloride is used in the manufacture
of car catalysts (Tables 4 and 5). Platinum complexes have been reported to be
added as catalysts in products used for example for coating in the textile industry
(Table 5) and to occur in products used for moulding in electronics plants (Table 5).
Platinum also might be used in Sweden e.g. in jewellery, but there are no reliable
figures on the amounts used for those purposes. Certain platinum compounds are
used as cytostatic agents (cisplatin and carboplatin), while platinum and hexachloro-
platinic(IV) acid have been reported to occur in homeopathic drugs (Swedish
National Chemical Inspectorate).
Smaller amounts of platinum and platinum compounds are used in industry in
Denmark (Table 6). According to the Danish Product Register platinum metal is
used in small concentrations in solder paste/welding materials and conductor paste
in the electroindustry, but the use of metallic platinum generally is not reported to
the register and thus platinum may be used in other industries as well. Potassium
hexachloroplatinate(IV) is used as a laboratory chemical and in very small concent-
8Table 3. Platinum sales to various types of industry in the USA before and after the
introduction of automobile catalytic converters (from 63)
Industry 1973 1987
kg/year % of total kg/year % of total
Automobile - - 18817 71.3
Chemical 7434 36.3 1920 7.5
Petroleum 3844 18.8 739 2.8
Dental and medical 868 4.2 479 1.9
Electrical 3642 17.9 1821 7.1
Glass 2255 11.0 285 1.1
Jewellery and decorative 697 3.4 177 0.7
Miscellaneous 1732 8.5 1430 5.6
Total 20472 100 25668 100
Table 4. Major uses of platinum and platinum compounds in industry in Sweden in
1993*
Industry kg Compound
Petroleum
Chemical
3050
67
Platinum
Platinum(II)oxide, platinum(II)sulphide, platinum
Metal finishing 250 Hexachloroplatinic acid
*Figures according to the product register from the Swedish National Chemical Inspectorate.
Table 5. Amount of platinum/platinum compounds in different products* used in
industry in Sweden in 1993
Function Compound Number
of products
Conc (%) Total
amount (kg)
Catalyst
Raw material
Platinum
Hexachloroplatinic  acid
4
1
<2
25
<3055
250
Catalyst Platinum(II) oxide 1 <1 <32
Catalyst Platinum(II) sulphide 1 <1 <32
Catalyst Platinum, 1,3-diethenyl-
1,1,3,3-tetramethyldisiloxane
complexes
1 4 4
Catalyst Platinum, chlorooctanol
complexes
2 <0.2 <0.8
*Figures according to the product register from the Swedish National Chemical Inspectorate.
9Table 6. Amount of platinum/platinum compounds in different products* used in
industry in Denmark in 1992
Function Compound Number
 of products
Conc. (%) Total
amount (kg)
Not given Platinum 25 - 2-3
Not given Potassium hexachloroplatinate 3 - 1-2
Catalyst Hexachloroplatinic acid 5 - <1
Catalyst Hexachloroplatinic acid hexahydrate 2 - <1
Catalyst Platinum, 1,3-diethenyl-1,1,3,3-
tetramethyldisiloxane complexes
6 - <1
Catalyst Platinum, carbonyl chloro 2,4,6,8-
tetraethenyl-2,4,6,8-tetramethyl-
cyclotetrasiloxane complexes
3 - <1
Catalyst Platinum, chlorooctanol complexes 1 - <1
*Figures according to the Danish Product Register.
rations in heating, water and sanitation products. Hexachloroplatinic(IV) acid and
different complexes of platinum are used in very small concentrations as catalysts in
raw materials used in the chemical industry and in silicon-based lubricant stuff and
polishing material used in the iron/metal industry and wood/furniture industry
(personal communication, O. M. Poulsen, National Institute of Occupational
Health, Denmark).
In Norway platinum metal, hexachloroplatinic(IV) acid, platinum(II) oxide, plati-
num(IV) oxide and an unspecified platinum complex are registered in the Product
Register (1996), but statistics on the amounts used are only available for hexachlo-
roplatinic(IV) acid (14 products) and the unspecified platinum complex (1 product).
These two platinum compounds are used in very small amounts mainly in varnish
and other products used for painting and constitute totally <<500 kg. The products
are used e.g. in chemical-technical industry, aircraft industry, during building/
constructing and for private use (personal communication, P. Kristensen, National
Institute of Occupational Health, Norway).
In Finland at least four products containing platinum are used as catalysts or labo-
ratory chemicals. Few data on the chemical composition or the amounts used have
been obtained, but it has been stated that 300 kg/year of tetraammineplatinum hyd-
rogencarbonate is used by a manufacturer of automobile catalyzers (personal com-
munication, V. Riihimki, Finnish Institute of Occupational Health).
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5. Occupational exposure
There are three primary categories of industrial sources for exposure to platinum:
mining, refining and processing. Platinum in the mining operation usually is found
in the insoluble form, as the free metal or in other forms which are very insoluble
(66). The refining operations provide the possible exposure of predominantly the
soluble forms of platinum, especially during the latter steps and the chief occupa-
tional exposure to chloroplatinic acid/complex halogenated salts of platinum (e.g.
ammonium and sodium hexa- and tetrachloroplatinate) is considered to occur in the
primary refining of platinum and during secondary refining, that is when platinum
is reclaimed from scrap metal and expended catalysts (including automobile exhaust
catalysts and catalysts used e.g in the oil refining industry) (7, 13, 27, 66, 120,
124). However, occupational exposure to hexachloroplatinic(IV) acid or platinum
salts also might be expected e.g. in the manufacture of emission control systems for
cars and catalysts for agricultural fertilizers, at small-scale plating or coating
operations, during laboratory handling and in the photographic industry (10, 42,
56, 90, 119, 150, 180). Exposure to certain platinum compounds (antineoplastic
drugs) also might occur in hospitals (34).
There is some information available regarding platinum levels in the work envi-
ronment (Table 7), but the exposure data may not be directly comparable due to
differences in sampling and analytical techniques etc. The contribution of soluble
platinum salts to the content of platinum in the atmosphere also is very different.
Few data concerning air levels of platinum in mines have been published. In one
study (65) air samples were collected from the mines in the Sudbury area in
Canada, during underground mining and in the building where the metals were
removed from the crushed ore slurry. The platinum levels generally were found to
be below the detection limit (<0.003 mg/m3), except in the precious metals area
where the air level of platinum was 0.377 mg/m3. However, the ore contained very
low levels of Pt as compared with South African ore which was 10-20 times higher.    
In platinum refineries the air levels of platinum have been found to be very vari-
able. Extremely high levels of platinum (5-80 mg/m3) were reported in a badly ven-
tilated platinum refinery in China, where the workers were exposed to dust or spray
of complex platinum salts and platinum metal. The average concentration at most
points was below 10 mg/m3 (149). In an American study (65) the platinum concent-
ration in air in a typical refinery in New Jersey was found to be between 0.02-0.26
mg/m3 (mean: 0.16 mg/m3) in the refinery section and 0.13-0.21 mg/m3 (mean: 0.18
mg/m3) in the salts section (sampling for 5 days). In two late German studies the air
levels of platinum also were stated to be very low. In one study (21) it was stated
that 2.0 mg/m3 was maintained over the long term, but two stationary air monito-
rings of total dust in the separation shop in 1986 for 2 h showed concentrations of
platinum salts of 0.08 and 0.1 mg/m3. Two personal air monitorings in filter press
workers for 1 h showed levels <0.05 mg/m3 (detection limit). Processes considered
to have relatively low or moderate exposure to platinum were e.g. alkaline dissolu-
tion of metallic platinum and manufacture of catalysts, while relatively high
11
Table 7. Workplace concentrations of platinum in various types of industries
Industry Process, work operation Concentration Ref
Mine mine, furnace room
precious metals area
<0.003 mg/m3
0.377 mg/m3
65
Platinum refinery refining of platinum-iridium alloy 5000-80000 mg/m3 149
Platinum refinery crushing (NH4)2(PtCl6)
discharging (NH4)2(PtCl6) fr ovens
sieving platinum metal
neutralizing platinum salts
other areas
<1700 mg/m3
>68 mg/m3
400-960 mg/m3
18-20 mg/m3
0.9-9.5 mg/m3
37,59
Platinum refinery salts section
refinery section
0.13-0.21 mg/m3
0.02-0.26 mg/m3
65
Platinum refinery generally <0.08 mg/m3 95
Platinum refinery separation shop
generally
0.08, 0.1 mg/m3
<2.0 mg/m3
21
Platinum refinery refining, catalyst manufacture
handling and dispensing of solids
and solutions
<2 mg/m3
<16 mg/m3
56
Platinum
recycling
industry
recovery
refinery
warehouse
analytical laboratories
other areas
2.7, 5.3 mg/m3
10.7, 27.1 mg/m3
8.6 mg/m3
0.4 mg/m3
0.5, 0.6 mg/m3
7
Precious catalysts
reprocessing plant
destruction of spent catalysts 40 - 240 mg/m3 47
Platinum
recycling
industry
cutting
cutting
draining
draining
generally
15 mg/m3
10 mg/m3 (in resp. dust)
71 mg/m3
24 mg/m3 (in resp. dust)
<1 mg/m3
*
Platinum metal
using industry
production of catalysts
grinding, polishing, cutting, sawing
recycling of platinum catalysts
0.3-19.9 mg/m3
1.8-3.1 mg/m3
3.8 mg/m3
139
Car catalyst
manufacturing
dilution of hexachloroplatinic acid,
coating of catalysts, packing area,
lab work
<0.4 mg/m3 42
Manufacture of
platinum-coated
oxygen sensors
0.14-1.83 mg/m3 56,148
*Gerd Sllsten, department of occupational medicine, Gothenburg, Sweden,
personal communication 1996.
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exposure was found in the platinum refinery (no more details known). In the
second study (95) platinum salt exposure in the different working areas had been
measured by the refinery and was generally below 0.08 mg/m3. However, the expo-
sure during the drying process of the salts was considered as too high. No further
details on the measurements were available. In a report from 1945, four British
refineries were investigated and estimations of the air levels of platinum were made
at different sampling points (37, 59). Air levels of less than 5 mg Pt/m3 were found
in the majority of the refining operations (wet processes and/or local exhaust venti-
lation), but levels up to 1700 mg/m3 were measured e.g. during crushing of ammo-
nium hexachloroplatinate(IV).
A recent document from the UK (56) stated, regarding exposure to soluble plati-
num salts, that about 96% of 8-hour TWA exposure measurements at refining and
catalyst manufacture were well below 2 mg/m3 (calculated from measurements of
exposure not available). The majority of exposures above this value occurred during
the production and dispensing of soluble platinum salts. However, there was a
higher percentage of results (10%) above 2 mg/m3, when the results were looked at
without reference to time-weighing and data relating to exposures of 1 to 4 hours
indicated numerical values up to 7 to 8 times the occupational exposure limit value
of 2 mg/m3 for the duration of the sampling period. There was also a wider range of
production areas which gave rise to these results, including process  catalyst pro-
duction, platinum recovery, platinum refining.
In an investigation in the USA, the air levels of platinum salts were measured in
1977-1979 (>75 air measurements), in a plant, that reclaimed platinum and other
precious metals from scrap metals and expended catalysts. Elevated platinum salt air
measurements were noted in the recovery, refinery and warehouse areas and the
mean air concentration (TWA 8 hr) often exceeded 2 mg/m3. It was estimated that
within a four-month period of measurements this value was exceeded between 50
and 75% of the time (7, 23). In an unpublished Swedish report (Gerd Sllsten,
personal communication 1996), platinum air levels between 15 and 71 mg/m3 was
found by personal sampling (197-305 min) in one worker during recycling of plati-
num catalysts. The Pt air levels were stated to be below Ê1 mg/m3 for the other few
workers. The exposure of workers to metallic catalyst dust was assessed in a
French study (47). In most instances other metals than platinum were measured, but
personal exposure of platinum for one worker at a precious catalysts reprocessing
plant, where metals were recovered by the destruction of spent catalysts, was re-
ported to be between 40 and 240 mg/m3 (sampling for 3 days). The concentration of
total platinum in air in the platinum metal using industry, determined by stationary
and personal sampling at several working sites (no details were given), was  repor-
ted in another study (139) to range between 0.3-19.9 mg/m3 (median 3.1 mg/m3)
during production of catalysts and 1.8-3.1 mg/m3 (median 1.8 mg/m3) during
mechanical treatment (grinding, polishing, cutting, sawing) of platinum containing
materials. A median value obtained in plants used for recycling of platinum catalysts
was 3.8 mg/m3.
The exposure to platinum during manufacturing of car catalysts was investigated
in a Swedish study (42). A solution containing hexachloroplatinic(IV) acid and
13
rhodium chloride ( 5:1) was used in the factory for the production of catalysts.
Personal sampling was undertaken e.g. during preparation of the platinum/rhodium
solution, analytical work, work in the box used for coating of catalysts, and during
packing of catalysts. The Pt values were found to be <0.2 mg/m3 (below detection
limit). When stationary sampling was used the air levels of platinum were given as
<0.4 mg/m3 during dilution of the platinum/rhodium solution and <0.2 mg/m3
during coating with the platinum/rhodium solution and in the packing area.
In a Japanese study (56, 148) the concentrations of platinum in the air during the
manufacture of platinum-coated oxygen sensors was measured. The industrial pro-
cess involved the application of 50% hexachloroplatinic(IV) acid solution to zirconia
porcelain, reacting the acid with ammonia to form ammonium hexachloroplati-
nate(IV) and calcining this to form a thin film of platinum. Measurements of the
concentrations of Pt in the air at the two electrodes ranged from 0.14 to 1.83 mg/m3
with 48-hour averages of 0.46 and 1.1 mg/m3. Cleaning of the sensors was stated to
involve exposure to fine dust of ammonium hexachloroplatinate(IV) at higher
concentrations than those in the workplace as a whole, but no quantitative values
were given in the study.
6. Sampling and analysis
One important method (MDHS 46) for determination of platinum metal and soluble
inorganic salts of platinum in air has been developed by the UK Health and Safety
Executive (22, 56). Air is drawn for two hours through a mixed-cellulose ester
filter, which is then treated with hydrochloric acid to dissolve soluble platinum
salts. The resultant solution is analyzed for platinum by graphite furnace atomic
absorption spectrometry (GFAAS) at a wavelength of 265.9 nm. Platinum metal
and insoluble salts are determined by dissolution in 50% aqua regia followed by
evaporation to dryness several times with concentrated hydrochloric acid before
proceeding as before. Another method (S191), enabling the determination of
soluble platinum salts and platinum metal together with insoluble platinum salts, has
been produced by the US National Institute for Occupational Safety and Health
(110). The aerosol fraction is collected on a mixed cellulose ester filter which is then
wet-ashed using nitric acid to dissolve the organic matrix. Soluble platinum salts are
taken up in a nitric/perchloric acid solution and platinum metal and insoluble plati-
num salts are dissolved in a nitric/hydrochloric acid solution. The resultant solutions
are analysed for platinum by GFAAS. The method has been validated with potas-
sium hexachloroplatinate(IV) over the range of 0.00079-0.0031 mg/m3 using a
720 L sample. The detection limit of the method (720 L sample) was 0.00014
mg/m3 (110).
Other methods for determination of platinum in air has been described more
recently by NIOSH (111) and OSHA (116). These methods according to HSE (56),
determine only total platinum and use analytical techniques (inductively coupled
plasma atomic emission spectrometry (ICP-AES), flame atomic absorption spectro-
metry (FAAS)) with a relatively poor detection limit for platinum in comparison to
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GFAAS. However, none of the above mentioned methods may be suitable for
determination of short-term activity-related exposure if the platinum concentration in
air is low. Sample solutions may then be analysed by inductively coupled plasma
mass spectrometry (ICP-MS), a technique which exhibits a significantly lower
detection limit for platinum than GFAAS (56). For further details on different
methods for determination of platinum and its salts in workplace air e.g. see refe-
rences 56 and 63.
Several techniques have been used to determine platinum levels in biological
samples (114). When flameless AAS was used for measurement of platinum in
tissues, the practical limit of the assay in one study (128) was estimated to be about
0.1 mg/g wet tissue (1-g tissue sample). Direct analysis allowed for determination of
as little as 0.02 mg Pt/g plasma (0.2-0.5 ml blood samples) (128). Other, more
sensitive methods enabling the determination of Pt at the mg/g to pg/g levels also
have been developed (11). One method based on adsorptive voltammetry (AV) is
extremely sensitive and is considered to allow a reliable determination of baseline
platinum levels (139). A detection limit for this method down to 0.2 ng Pt/L for
urine (sample volume: 10 ml) and 0.8 ng Pt/L for blood/blood plasma (samle
volume: 3 ml) has been reported (96). The detection limit for platinum in blood,
when an AV method was used by Nygren et al (114), was 0.017 mg/L (100 ul
sample). Radiochemical neutron activation analysis (RNAA) and ICP-MS are other
methods for determining traces of platinum (63, 96, 98). For ICP-MS the limit of
detection is in the order of 0.01 mg/L (164). A good correlation between ICP-MS
and AV was shown in a study by Nygren et al (114). Currently there are no external
quality assessment schemes for analysis of platinum in biological fluids. Suitable
standards for internal quality control have according to HSE been identified from
the National Bureau of Standards (USA) as spiked and normal urine (56).
7. Toxicokinetics
7.1 Uptake
The uptake of platinum compounds is dependent on the physicochemical properties
of the compound and the route of administration.
In general deposits of insoluble metallic compounds in the airways are more
likely to be cleared by the mucociliary apparatus, while soluble metallic salts may
readily dissociate and be transported as metal ions into lung tissues (13). However,
no quantitative data concerning absorption of platinum compounds via the lungs
have been found. Excretion data on male rat (Charles River CD-1) indicated that
most of the inhaled particles (5-8 mg/m3; 48 min) of platinum metal, platinum(IV)
oxide, platinum(IV) sulphate (1.0 mm) and platinum(IV) chloride (1.0 mm) was
cleared from the lungs by mucociliary action, swallowed and excreted via the faeces
(101). The presence of 191Pt in the blood (counted only after exposure to platinum
metal) and the urine indicated the absorption of a small fraction of 191Pt, although it
was impossible to determine the relative contributions of lung and of gastrointestinal
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Table 8. Percentage of initial lung burden retained with time in the lungs (from 101)
Time Portion of Pt burden retained (%)
(days) Platinum metal Platinum oxide Platinum sulphate
1 63.0 57.2 73.7
2 49.5 60.9 43.4
4 41.3 49.0 20.4
8 42.9 28.6 -
16 28.0 17.9 4.4
absorption to the total body burden (101). Retention data (Table 8) for platinum(IV)
sulphate, platinum metal and platinum(IV) oxide indicated, that the water-soluble
compound (platinum(IV) sulphate) was more rapidly mobilized from the lung than
the other two compounds.
Gastrointestinal absorption has been studied to some extent in animal
experiments. In one study (99, 100) less than 1% of the initial dose (25 mCi) was
roughly calculated (whole-body retention data) to have been absorbed through the
gastrointestinal tract in rat after a single administration of platinum(IV) chloride. In
another study (19) platinum metal or platinum(IV) chloride was given in the diet in
five different concentrations to female rat from four weeks before pregnancy to the
twentieth day of gestation. A much better uptake, reflected as a higher concentration
of platinum in blood and selected tissues was found for the water-soluble salt, but
the total amount absorbed through the gastrointestinal tract (not given) seemed to be
small. Other data concerning blood levels of Pt and organ distribution of Pt in small
rodents after administration of platinum compounds (e.g. 50, 85) also show peroral
absorption, but no percentages are given. Peroral uptake of Pt probably is depen-
dent i.a. on the particle size, since in one study on platinum metal (6), administra-
tion of smaller particles (0.5 mm) led to a higher Pt retention, than larger particles
(150 mm).
In contrast to the limited experimental data indicating a small peroral uptake of
platinum and soluble salts of platinum, excretion data in a study on humans showed
a large peroral uptake of platinum (168). When the amount of Pt excreted in urine
during 24 h was measured it was found to represent at least 42% of the platinum in
a hypothetical diet for an adult male. Further studies with more subjects receiving
diets with known platinum contents would be required to make more reliable
conclusions on uptake.
No quantitative data on skin resorption have been found, but in a Russian study
(133) dermal application of ammonium chloroplatinate (and a palladium compound)
was reported to be accompanied by reduced body-mass gain in the experimental
animals (species not given). After termination of the experiment platinum was found
in all internal organs examined as well as in urine and blood. No further details of
the study are given, and e.g. the contribution of peroral uptake cannot be excluded.
In a skin sensitisation study on guinea pigs and rabbits for US EPA, no platinum
could be detected in urine, serum or spleen, following repeated dermal application
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of 0.1 g or 0.25 g platinum(IV) sulphate, thus suggesting little or no dermal
absorption of this platinum salt (157). However, the platinum level in spleen was
assessed about 14 days after the last application of platinum paste (and after the skin
test procedure).
7.2 Distribution
In vitro studies have shown that ammonium tetrachloroplatinate(II) and potassium
tetrachloroplatinate(II) bind to serum albumin and transferrin (40, 156, 165). In
human blood samples most of the platinum was found to be associated with protein
and about 65-80% of the platinum was found to be located in the erythrocytes
(168). Erythrocytes were also found to contain more platinum (platinum(IV) chlo-
ride, platinum metal given perorally) than plasma in a study (19) in rat (Sprague-
Dawley, females).
The route of administration is important in determining the retention of platinum.
In studies in male rat (Charles River CD-1) the whole-body retention of 191Pt
(platinum(IV) chloride; single exposure) has been shown to decrease in the
following manner: intravenous > intratracheal > inhalation > oral (99, 100, 101).
There is a time differential in the attainment of maximum Pt levels among different
organs/tissues and the distribution of platinum compounds also changes with dose,
but generally the greatest accumulation after absorption has been shown in the
kidney (6, 19, 50, 85, 99, 100, 101, 130).
Experiments with labelled platinum(IV) chloride showed that after intravenous
dosing (25 mCi) to rats, radioactivity was found in all the tissues analyzed. The
concentrations were higher than in the blood, during the first 7 days after exposure,
in the liver, spleen, adrenal gland and kidney, whereas low levels were found e.g.
in fat. The large amount of radioactivity found in the kidney (day 1: 6.7% per gram;
day 14: 1.2% per gram) suggested that this organ accumulated 191Pt. The lowest
amount of radioactivity was found in the brain, indicating that 191Pt was transferred
only to a limited extent through the blood-brain barrier (99, 100). The percentage of
absorbed dose in liver, muscle, kidney, blood and bone, one day after an intra-
venous administration of labelled sodium tetrachloroplatinate(II) (dose not given),
was reported in another study in rat (female albino) and constituted about 13, 12,
10, 7 and 6%, respectively. It was also stated (no details were given) that decrease
in tissue content of Pt roughly paralleled the decline of the blood concentrations and
that Pt was easily measurable in the blood as long as 32 days after injection (33).
Exposure to platinum compounds through inhalation has been found to lead to an
accumulation in the gastrointestinal and respiratory tract immediately after exposure.
In a study in male rat (Charles River CD-1) with 191platinum metal or 191platinum
oxide (7-8 mg/m3; 48 min; particle size not given) it was shown, that the initial lung
burdens for 191Pt metal and 191platinum oxide represented about 14% and 16% of
the initial body burdens (101). Most of the radioactivity had been eliminated from
the gastrointestinal tract within 24 h, while the lung still contained about 60% of the
initial lung burden (Table 8). In addition to the lungs and trachea, the kidney and
bone was found to contain the highest concentrations of radioactivity (platinum
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Table 9. Radioactive 191Pt in selected tissues following inhalation exposure to Pt metal
(from 101)
Tissues Days after exposure
1 2 4 8
Blood 61* 43 30 12
Trachea 1909 2510 738 343
Lung 45462 28784 28280 23543
Liver 52 46 37 17
Kidney 750 1002 906 823
Bone 281 258 231 156
Brain 5 3 1 0
Muscle 22 10 28 0
Spleen 39 73 23 5
Heart 37 58 23 5
*mean counts per gram
metal) when 191Pt was counted in selected tissues 1-8 days after exposure (Table 9).
The brain contained very small amounts of 191Pt (101).
Peroral administration to rat has shown, that administration of a water-soluble salt
such as platinum(IV) chloride lead to much higher concentrations of platinum in the
blood and tissues, than administration of platinum metal (at comparable doses), but
the particle size has been found to influence the concentration of Pt metal, especially
in the kidneys (6, 19). In these and other animal experiments the absorbed Pt has
been shown to be generally distributed and usually the highest amounts of Pt
(platinum metal, platinum(II) chloride, platinum(IV) chloride or platinum(IV)
sulphate) have been found in the kidney, while low levels have been found in
adipose tissue and brain (5, 6, 19, 50, 85, 99, 100, 130).
Foetal uptake of platinum compounds has been investigated in a few studies and
found to be very low. In one study (99) rats were given 25 mCi 191platinum(IV)
chloride intravenously and were killed 24 h later. Very small amounts of 191Pt were
present in all the foetuses counted and averaged 0.01% of the dose/g in whole foetal
tissue and 0.05% of the dose/g in foetal liver. Placental levels were relatively high
(0.92% of the dose/g) and only the maternal liver (1.44% of the dose/g) and mater-
nal kidney (4.22% of the dose/g) had higher concentrations than the placenta (99).
In an unpublished study in mice (88) it was found, that placental Pt levels were
greater than blood levels (most obvious a few days after administration) when
sodium hexachloroplatinate(IV) was administered subcutaneously at the LD1 level
(22 ppm (mg/kg bw) Pt) on days 7 or 12 of gestation. The Pt levels in foetus and in
the suckling offspring of dams receiving a single dose of sodium hexachloro-
platinate(IV) day 2 post partum were low. In another study in rat (76) platinum(IV)
chloride or platinum metal was given in the diet in five different concentrations (up
to 100 mg/kg diet) from four weeks before pregnancy to the twentieth day of gesta-
tion. The concentration of Pt in uterus and in the foeto-placental unit generally was
much higher in the platinum(IV) chloride groups than in the corresponding platinum
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metal groups, but still constituted a very small part (e.g. <=0.006% in amnion) of
the ingested amount of Pt. The highest Pt concentration (both compounds) in the
foeto-placental unit was found in amnion, where about 80-90% of the measured
platinum was situated. The lowest Pt content was found in the foetus (above the
detection limit only in the 50 and 100 mg/kg groups given platinum(IV) chloride).
When platinum(IV) chloride or platinum(II) chloride was given in concentrations up
to 100 mg/kg diet to lactating rats only platinum(IV) chloride was detected in the
milk (at the 50 and 100 mg/kg level), but platinum could be determined in the car-
cass of the offspring after administration of platinum(IV) chloride as well as plati-
num(II) chloride (at the 50 and 100 mg/kg levels). The level of Pt in the offspring
was found to be highest at the end of the lactation period and generally the platinum
content was higher in the offspring after administration of platinum(IV) chloride
(77).
Human tissue burden of platinum was determined in 1313 samples (97 indivi-
duals) through autopsy tissue analysis in California in 1974-1975, when catalytic
converters still were uncommon (32). In 46% of the individuals Pt was detected in
one or more tissues (about 5% of the samples). The range of the platinum
concentrations detected was 3 to 1460 ng/g wet tissue. Tissues in which the highest
concentrations of platinum were found were, in descending order: subcutaneous fat,
kidney, pancreas, and liver (32). One sample out of nine analysed showed the
presence Pt in the brain. The presence of platinum in subcutaneous fat was
surprising. Conversion of lipid-insoluble platinum compounds to lipid-soluble
compounds e.g through methylation possibly could be an explanation, but the
analytical accuracy has been questioned and contamination of the samples
suspected. When analysis of platinum content in autopsy tissue samples (liver,
kidney, spleen, lung, muscle, fat) from 10 people in California (1974) were made
by another laboratory, the concentrations of Pt were determined to be considerably
lower and below the limit of detection for all the samples (e.g. <3 ng/g (<2.6 ppb)
wet tissue in the kidney) (65). The platinum level in tissues of about 40 persons
with no known occupational exposure to metals was also determined in a late
Japanese study (181). The platinum levels were found to be up to 1170 ng/g wet
weight in liver and decreased in the following order: liver, kidney cortex (<330
ng/g), spleen (<320 ng/g), heart (<316 ng/g), and kidney medulla (<145 ng/g)), but
platinum was detected only in a few persons. In the brain (cerebrum, cerebellum)
none of the samples were above the lower limit of determination (27 ng/g wet
weight) (181). In contrast, the platinum level in liver (11 samples from 1980) in
another study in human was very low: from 0.005 to 0.057 ng/g wet weight (183).
The Pt level in human heart (n=9), determined in a Swedish study (175), was 0.5-
1.2 ng/g wet tissue. In one study (65) the results of analysis of tissue samples from
nine individuals previously employed by mining and ore processing plants in
Canada were presented, and it was shown that detectable concentrations of platinum
only were found in three samples (lung: 3.7 ng/g (ppb), fat: 4.5 ng/g (ppb),
muscle: 25 ng/g (ppb)).
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7.3. Elimination
Excretion, following intravenous administration to male rat (Charles River CD-1) of
labelled platinum(IV) chloride, was shown in one study (100) to occur both in the
urine and faeces, but the urine contained a greater quantity of radioactivity. The
whole-body retention after three days was 65% and after 28 days about 14%. In
another study in rats (female albino) about 40% of an injected dose of labelled
sodium tetrachloroplatinate(II) was stated to have been eliminated in urine and
faeces in 24 h and 92% in 32 days (33). When 191platinum(IV) chloride was admi-
nistered perorally to male rat (Charles River CD-1) most of the 191Pt was eliminated
in the faeces and only a small amount was excreted in the urine. This was probably
due to passage of unabsorbed 191Pt through the gastrointestinal tract and was in
accordance with the rapid decline of the whole-body retention curve to less than 1%
at the end of three days (99, 100).
Radioactivity in the urine and faeces samples from rats (males; Charles River CD-
1) following inhalation exposure for 48 minutes to particulates of platinum(IV)
chloride (5.0 mg/m3), platinum(IV) sulphate (5-7 mg/m3), platinum(IV) oxide
(7-8 mg/m3) or platinum metal (7-8 mg/m3) pointed to that most of the 191Pt was
eliminated in the faeces during the first days. However, there were small amounts
of radioactivity present in the urine too (101). Whole-body retention curves showed
an initial rapid clearance of 191Pt from the body followed by a slower clearance
phase during the remainder of the post-exposure period. The whole-body retention
of 191Pt measured as a percentage of the initial body burden 24 h after exposure to
platinum(IV) chloride, platinum(IV) sulphate, platinum(IV) oxide and platinum
metal was 41, 33, 31, and 20%, respectively. After 10 days around 7-8% of the
initial 191Pt was retained, except after inhalation of platinum(IV) chloride where only
about 1% was retained (101). The clearance of 191Pt from the lungs also could be
divided into an initial rapid phase (24 h) and a later slow phase. For the slow phase,
the clearance half-time was about eight days (101).
Excretion in human has been estimated to some extent and limited data point to a
slow elimination of platinum metal. In one study (4) no obvious difference of the
platinum content before and after an exposure-free period (15 days) could be
shown, when platinum was measured in the urine (and serum) of four workers
occupationally exposed to platinum metal. In concordance with this, increased
urinary values of Pt was found in one worker exposed to platinum during recycling
of platinum catalysts (cutting, draining), while no definite decrease in urinary levels
of platinum was seen during an unexposed period (at least 12 days) (Gerd Sllsten,
personal communication). The urinary excretion of platinum was estimated in one
adult male from Sydney (with no occupational exposure of platinum compounds)
and found to be between 0.76 and 1.07 mg/day (168). However, the values
obtained in this study are very high compared to the values of Pt content in urine
obtained by some other authors (see Section 8 Biological Monitoring).
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8. Biological monitoring
Reference values of platinum in blood and urine have been estimated in some
studies in recent years, but there are large discrepancies in the results obtained by
different authors. In an Australian study (168) baseline levels of platinum in the
blood, hair and urine were determined by a method based on AV. The mean con-
centrations of platinum in samples from residents (n=21) in Sydney were 0.60 mg/L
(range 0.09-1.72 mg/L) in whole blood, 4.90 mg/kg (range 0.87-18.31 mg/kg) in
hair and 0.33 mg/g creatinine (range 0.03-0.82 mg/g creatinine) or 0.25 mg/L (range
0.02-0.92 mg/L) in urine. No relationships between the platinum levels in blood,
hair and urine were observed and no differences between samples obtained from
Sydney and from a relatively unpolluted area in Australia were found. As another
part of this study the level of platinum in blood was measured in subjects from
Ume in Sweden (n=10), and the blood levels were found to be about the same as
in Australia (mean, 0.58 mg/L, range 0.12-1.58 mg/L) (113). In an earlier study
(114) the natural levels of platinum determined by AV in human blood (n=18) and
urine (n=11) were found to be in the range of 0.1-2.8 mg/L (median 0.59 mg/L) and
0.04-0.61 mg/L (median 0.11 mg/L), respectively. The levels of platinum in blood
in the above mentioned studies were close to the levels (determined by AAS) found
in 750 ml composite blood samples collected in USA in 1974, when few car
catalysts were used. The blood levels of platinum obtained from a population living
near a heavily travelled urban freeway in Los Angeles, California and from a
population in the high desert area were 0.49 mg/L  and 1.80 mg/L, respectively
(67).
In a recent German study (96) "normal" values for platinum in blood (n=13) and
urine (n=14) determined by a method based on AV were much lower, than in the
above mentioned studies, and ranged from <=0.8 to 6.9 ng/L in whole blood or
plasma and 0.5 to 14.3 ng/L (mean 3.5 ng/L) in urine. It was also stated, that a sig-
nificant correlation was evaluated for the relationship between the platinum levels in
blood, serum and urine (139). The higher baseline levels obtained by Nygren,
Vaughan et al (113, 114, 168) were not considered by these authors (96, 139) to
correspond to the concentrations of platinum in the earth«s crust, but no explanation
for the differences was given. When blood samples from three persons not
occupationally exposed to platinum was collected in Sweden in 1993, and some of
these samples were analyzed in laboratories in Ume (Sweden) and Dortmund
(Germany) by the same method (AV) and in Lund (Sweden) by a different method
(ICP-MS), the results were found to differ greatly, even though the same tubes for
blood sampling had been used (Gerd Sllsten, personal communication). The single
value obtained from Lund and the values obtained from the German laboratory were
much lower than the corresponding Ume values. Furthermore, there were rather
large fluctuations in some of the values obtained from Ume. These data further
support the assumption that the correct base value in blood is very low - in the order
of some nanogrammes per litre. The Pt level in urine of one control subject also was
determined (ICP-MS; Lund) and found to be 10-30 ng/L (Gerd Sllsten, personal
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communication). In a recent study concerning exposure to platinum-containing
antineoplastic drugs in hospital pharmacy personnel and nurses (34), the mean uri-
nary platinum level in controls (n=11) (determined by voltammetric analysis after
UV photolysis) was 5.3 ng/L (range 2.1-15.2 ng/L or 2.3-10.4 ng/g creatinine).
Some studies have shown elevated levels of platinum in blood or urine (compared
to control subjects) in occupationally exposed persons. In one study (139) the plati-
num levels were determined by AV for 40 employees exposed to metallic platinum
during manufacturing and recycling of platinum containing catalysts or mechanical
treatment of platinum containing materials (no data concerning exposure time were
given). The platinum levels of the exposed workers were elevated and ranged from
10-9200 ng/L in urine (mean values: 1260 ng/L-production; 330 ng/L-recycling;
429 ng/L-mechanical treatment), 2-180 ng/L in blood (mean values: 39 ng/L-
production; 125 ng/L-mechanical treatment) and 4-280 ng/L in serum (mean values:
39 ng/L-production; 75 ng/L-mechanical treatment). A significant correlation was
evaluated for the relationship between the platinum levels in blood, serum and
urine, but no significant relationship could be found between the ambient air plati-
num levels and the concentrations in blood, serum and urine. Ranges for platinum
concentrations in air were 0.3-19.9 mg/m3 (median 3.1 mg/m3) during production of
catalysts and 1.8-3.1 mg/m3 (median 1.8 mg/m3) during mechanical treatment. A
median value for recycling was also given: 3.8 mg/m3 (139). Similar values were
presented in another study published by the same authors (96), but there are some
discrepancies in the lower range values of urine, blood and plasma of exposed per-
sons as well as in the number of samples. In a pilot study (173), probably part of
the above mentioned German studies, platinum levels in urine for 21 exposed men
were 20-630 ng/L (median 320) during recycling, 70-1350 ng/L (median 280)
during processing and 10-2900 ng/L (median 330) during mechanical treatment.
The values for platinum levels in blood and serum were between 100 and 280 ng/L
and the air levels of platinum between 1.7-6.0 mg/m3. However, in this work it was
stated, that a significant correlation between blood/serum platinum levels and air
platinum levels was apparent, whereas no significant correlation between blood and
urine was found. In an unpublished Swedish report (Gerd Sllsten, personal com-
munication) the urinary concentration of Pt in one worker, measured by ICP-MS,
exposed to total platinum air levels between 15-71 mg/m3 during recycling of
platinum catalysts (cutting, draining) was 150 ng/L.
In a study from the USA (14) sera of 12 current workers exposed to soluble pla-
tinum salts in a platinum refinery and three former workers  (all 15 were skin-test
positive) were analyzed by flameless AAS for Pt. Sera from eight persons had
detectable levels of Pt (ranging from 150 to 440 ng/g (ppb)). The mean level of Pt
in the sera of the current exposed workers was 240 ng/g (ppb). Pt concentrations in
the sera of three terminated and four presently employed workers were at or below
the lower limit of detection by this method. No measurements of the air levels of
platinum were presented. When samples of blood and urine were collected from
refinery workers (n=61) at a refinery in New Jersey, the levels of platinum in blood
were below the detection limit (<1.4 ng/g (ppb)), whereas about 10% of the urine
samples (6/58) had measurable amounts of platinum (0.23-2.58 mg/L; detection
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limit 0.1 mg/L). The air levels of platinum in the refinery section and the salts sec-
tion were 0.02-0.26 mg/m3 (mean: 0.16 mg/m3) and 0.13-0.21 mg/m3 (mean:
0.18Êmg/m3), respectively (65). The platinum content in urine in these areas were:
0.49 and 0.66 mg/L (refinery), and 1.22 and 1.24 mg/L (salts section). Samples of
blood, urine, faeces and hair from 49 workers in mining and ore processing
working in Canadian mines were also collected. It was found that the platinum
content in all the samples were below the limits of detection (e.g. blood <0.0014
mg/g (ppm) in a 15 ml sample, urine <0.00002 mg/g (ppm) in a 1 L composite
sample). Air samples collected during underground mining and in the building
where the metals were removed from the crushed ore slurry generally also showed
platinum levels below detectable levels (<0.003 mg/m3), but in the precious metals
area the platinum level was considerable higher: 0.377 mg/m3 (65).
Due to analytical problems and difficulties in establishing a reference value for
platinum in blood and urine no method can yet be used routinely for the monitoring
of platinum. Methods based on AV are extremely sensitive, but must be further
evaluated before they can be handled reliable in practice. Most other available analy-
tical methods do not have the required sensitivity for monitoring of low levels of
platinum in occupationally exposed workers.    
9. Mechanisms of toxicity
Platinum salts may induce bronchoconstriction, anaphylactic shock and elevated
plasma histamine levels in animals (monkey, dog, guinea-pig, rat) at the first con-
tact and without any previous exposure to platinum salts, thus through pharma-
cologic or irritant mechanisms (17, 120, 136). In one study (136) it was shown,
that an intravenous injection of 1-2 mg/kg sodium chloroplatinate in guinea-pigs
was followed by bronchospasm as intense as if it was caused by the injection of 5
mg/kg of histamine dihydrochloride. A peculiarity was that the action of the chloro-
platinate was exhausted after a few injections and the animal could resist a lethal
dose of the salt. The previous injection of an antihistamine also protected the animal
completely against the action of sodium chloroplatinate (120). The liberation of
histamine from guinea-pig was reported by the authors (136) to be restricted to the
chloroplatinate complex (PtCl6
2-), whereas the chloroplatinite (PtCl4
2-) was said to
be devoid of this property both when tested in vitro and in vivo (20 mg/kg);
however, no further details are given in the study. Other data, indicating that
sodium hexachloroplatinate(IV) is a primary respiratory irritant producing broncho-
constriction was shown by Biagini et al (15). Pulmonary function was evaluated in
a group of male Cynomolgus monkeys following acute serial bronchoprovocation
challenges (inhalation of aerosol) using increasing concentrations of methacholine
and a few weeks later sodium hexachloroplatinate(IV). The results showed (both
compounds) concentration-dependent increases in mean values for pulmonary flow
resistance (RL) and decreases in dynamic compliance (CLdyn), but the variation in
results of RL between individual animals was large. Concentration-dependent
reductions were also found in maximal expiratory flow volume (MEFV) perfor-
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mance parameters, and these data indicated that there were differential mechanisms
of pharmacologic action for the bronchoconstrictive effects of the two compounds
in monkeys.
However, in man the platinum salt-induced reactions of the respiratory tract and
the skin generally is considered to be of immunologic origin, although the precise
mechanism of sensitisation is still unclear (81, 94, 103, 118, 125, 144, 177). The
symptoms appear to start after a sensitising period and only a fraction of exposed
subjects become sensitised. Furthermore, the affected individuals become more and
more sensitive to platinum and react to levels far below those normally encountered
at work (17, 81, 95,120, 135, 136, 140, 177). Both atopic and nonatopic workers
may be affected (23, 95, 115, 170) and smoking appears to predispose individuals
to the development of platinum salts sensitisation after occupational exposure (7,
23, 84, 170). Tobacco smoke is believed to induce an increase in the permeability
of the respiratory epithelium (7, 53, 184) and it has been proposed, that concurrent
exposure to irritants (e.g. chlorine, ammonia, ozone) potentiate the effects of plati-
num salts exposure in the same way (7, 109).
An immunological reaction with platinum salts has been established in many
cases in man by skin prick testing (type I reaction) with inorganic platinum salts
(test sustances usually ammonium, sodium or potassium hexachloroplatinate(IV)
or tetrachloroplatinate(II)), but sometimes pulmonary reactivity (expressed in
bronchial provocation tests or as work-related symptoms) precede skin test
reactivity or occur in workers with negative skin tests and there is a possibility that
the initial pulmonary response is a sign of a hyperreactive pharmacologic effect
rather than an immune effect. Otherwise there are different rates of dermatologic and
pulmonary sensitisation (14, 15, 21, 23, 27, 29, 31, 58, 94, 95, 107, 115, 127,
129, 170, 177). There are other tests (mainly in vitro tests) indicating an IgE-
mediated reaction too. However, the sensitivity and reliability of the skin prick test
has not been equalled by any in vitro tests available (95, 135, 141). For example the
presence of platinum salt-specific IgE antibodies in serum (exposed workers) has
been demonstrated in vitro in radioallergosorbent tests (RAST)/ enzyme immuno-
assays (14, 21, 23, 29, 107, 125, 126, 182). A nonspecific immunopotentiation of
an IgE response also has been proposed as a possible mechanism of sensitisation,
since unusually high levels of total serum IgE has been noted in platinum metal
refinery workers in many studies and atopic individuals usually have been
eliminated during pre-employment screening in recent years (14, 21, 29, 95, 106,
107, 177).
In general, small molecular allergenic substances combine with large molecular
carrier substances, mainly protein, to form complete antigens (act as haptens) which
then can provoke a specific immune response. It has been shown in vitro, that plati-
num salts bind to e.g. serum albumin and transferrin, a major transport protein for
several metal ions (27, 29, 38, 40, 156, 165, 177, 182), and probably the strength
of the platinum-ligand bond, the reactivity of the complex towards protein or other
carrier molecules and the ability of platinum to form stable complexes with e.g.
proteins is of great importance for the allergenic potential of a platinum complex (1,
27). In a study in platinum refinery workers, known to be sensitive to hexachloro-
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platinate or tetrachloroplatinate salts, a series of platinum complexes was used for
skin prick tests (27). The results showed that the allergy-eliciting compounds only
were confined to a small group of ionic complexes containing reactive halogen
ligands. The chloroplatinates ((PtCl6)
2-; (PtCl4)
2-) were highly allergy eliciting and
an allergenic response was obtained whenever at least one chloro ligand was present
in a charged complex. The platinum(IV) and platinum(II) chloro species appeared to
be equally effective possibly due to in vivo reduction of platinum(IV) to plati-
num(II). Changing from chloro to bromo ligands maintained the response but at an
apparently reduced level. Neutral complexes and those containing more strongly
bound ligands with poor leaving abilities were inactive immunologically, presu-
mably due to little or no reaction with proteins. For example the leaving groups
such as nitro- and thiocyanato- are much less reactive than the halogens and simi-
larly the platinum amine linkage is very stable (27). However, antibody specificity
factors may have played a role in the elicitation of reactions.
Platinum complexes preferentially bind to nitrogen and sulfur in proteins (108).
The interaction with amino acids may lead to other effects than those depending on
sensitisation e.g. reduced enzymatic activity (91). Inhibition of malate dehydro-
genase, an enzyme active in the general metabolism, was shown in studies in vitro
and the electrostatic charge of the platinum compound was found to be an important
factor which influenced the degree of enzyme inhibition (162). The association
constants were greatest for the dinegatively charged state, regardless of the valence
state of the platinum, while there were no significant values for positively charged
complex ions. Thus, PtCl4
2-, PtCl6
2-, PtBr6
2- and PtBr4
2- were most tightly bound to
malate dehydrogenase in vitro and were strong enzyme inhibitors (39). In studies in
vivo some dinegatively charged complex salts of platinum (K2PtCl4, K2PtCl6) have
been shown to affect enzymes regulating the haeme pathway (see Section 10.7.
Other Studies). Furthermore, in an in vitro study, potassium tetrachloroplatinate(II)
was shown to weaken the interactions of serum albumin with other molecules like
haeme or bilirubin (165). Effects on enzymes have also been demonstrated with
other platinum compounds. Thus, platinum(IV) chloride has been found to affect
drug metabolism and to inhibit DNA synthesis in rat (see Section 10.7. Other
Studies).
Platinum compounds may also be reactive towards DNA (73). The chemical
reactivity of the complexes differ very much and is dependent on the ligands (28).
The interaction of the antineoplastic drug cisplatin with DNA has been extensively
studied. Aspects of the molecular mechanism involve passive diffusion of the
neutral complex across the cell membrane followed by hydrolysis and subsequent
binding of the aquated platinum complex to DNA (24, 176). Some of the neutral
platinum complexes, like cisplatin, are strong mutagens, and there seems to be a
common pattern between mutagenic potency and antitumor activity in the cis-
PtN2X2-type complexes (166). The mechanism of the mutagenic activity for com-
pounds like cisplatin is believed to occur through the reaction with DNA by dis-
placement of both chlorine atoms and subsequent chelate formation between N7(G)
and O6(G) sites (166). DNA-binding experiments and metabolism studies in vivo
and in vitro with some platinum(IV) complexes (iproplatin and tetraplatin), suggest
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that this kind of complexes is reduced to divalent metabolites able to react with DNA
(41, 122, 123). The interaction of complex or simple salts of platinum with DNA
has not been very well investigated, but some soluble platinum salts like
platinum(IV) chloride, platinum(IV) sulphate, potassium hexachloroplatinate(IV),
potassium tetrachloroplatinate(II) and ammonium hexachloroplatinate(IV) have been
found to be mutagenic/genotoxic in vitro (26, 71, 72, 137, 151, 158, 159, 160,
161, 179).
10. Effects in animals and in vitro studies
10.1. Irritation and sensitisation
In a study on male albino rabbits (25) dermal irritancy (intact skin) and cellular toxi-
city (abraded skin) of platinum(IV) chloride, platinum(II) chloride and platinum(IV)
oxide was tested. 0.1 g of the compound was mixed with 0.1 ml water and spread
over an abraded or intact site, which was immediately covered. The skin reactions
were evaluated and scored after 24 h and then 48 h later. Platinum(IV) chloride was
judged as irritant on intact skin, whereas platinum(II) chloride and platinum(IV)
oxide were considered as essentially nonirritant. Unpublished data (cited in 56, 63)
on skin irritation (patch tests on rabbits; 24 h contact or 4 h contact) and eye irri-
tation (rabbits) for some other platinum compounds are summarized in Table 10.
Irritation of the eyes and respiratory tract during exposure to ammonium hexa-
chloroplatinate(IV) was reported in a russian study (133), but no details e.g. on
exposure time, animal species or methods were given. 35 mg/m3 was considered as
a threshold concentration for an effect on the mucous membranes of the eyes.
An intense attack of asthma occurred in guinea-pigs, when the animals were
exposed to an aerosol of sodium hexachloroplatinate(IV) (no dose given) or the
compound was injected intravenously (10-20 mg/kg). Bronchospasm was also
noted after a single intravenous injection of 1-2 mg/kg sodium hexachloro-
platinate(IV), but after repeated doses of the chloroplatinate the response dis-
appeared (120, 136). When sodium hexachloroplatinate(IV) was tested in rats it
was shown to be less active than in guinea pigs, but pruritus of the muzzle and the
feet, cooling of the extremities and increased histamine levels in plasma was
demonstrated, when 40 mg/kg of the salt was injected intravenously. The intra-
venous injection of 30 mg/kg sodium hexachloroplatinate(IV) into an anaesthetized
dog led to death after some minutes. The histamine content of the whole blood
(expressed as dihydrochloride) increased considerably from 20 to 1000 mg/L in
2-5 minutes. No histamine release was found in another dog at the dose level
10 mg/kg (136).
Pulmonary hyperreactivity expressed as significantly increased average pulmo-
nary flow resistance (RL) and decreased forced expiratory volume (FEV0.5/FVC)
was found in male Cynomolgus monkeys challenged with sodium hexachloro-
platinate(IV) aerosols (up to 62.5 mg/ml solutions) 2 weeks after a period of
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Table 10. Skin and eye irritation by platinum compounds*
Compound Score
(skin)
Skin irritation test
classification
Eye irritation test
classification
Platinum (IV) oxide 0 non-irritant** -
Platinum(II) chloride 0.2 non-irritant** -
Platinum(IV) chloride 1.8 mild irritant** -
Ammonium hexachloroplatinate(IV) 1.3 mild irritant -
Ammonium tetrachloroplatinate(II) 2.7 slight irritant*** corrosive
Sodium hexachloroplatinate(IV) 0.5 mild irritant irritant
Sodium hexahydroxyplatinate(IV) 5.4 severe irritant    -
Potassium tetrachloroplatinate(II) 0 non-irritant irritant
Potassium tetracyanoplatinate(II) 0.3 mild irritant irritant****
Tetraammineplatinum(II) chloride 2.8 moderate irritant strongly irritant
Diamminedinitroplatinum(II) 0 non-irritant severely irritant
*Unpublished data cited in 63. Tests on rabbits were carried out according to US Federal Register
1973 guidelines (skin and eye tests) or according to OECD Test Guideline no 404 (skin) or 405
(eye).
**25. The given primary irritation score refer to intact skin.
***It is stated in 56, that this compound produced pronounced skin irritation.
****It is stated in 56, that this compound would not be classified as irritant to the eye according to
current EC classification criteria.
repeated inhalation exposure to about 216 mg/m3 of the platinum salt (4h/day,
biweekly for 12 weeks; particle size (MMAD) 1.61 mm), while no signs of
bronchial hyperreactivity (compared to control group mean responses) was found at
an exposure level around 1940 mg/m3 (MMAD 1.27 mm) or after percutaneous
exposure (1 ml of a solution of 20 mg/ml Na2PtCl6 biweekly for 12 weeks).
However, marked effects on the pulmonary function was found in all exposed and
control animals challenged with the platinum salt (controls: significant impairments
after challenge with the highest concentration of Na2PtCl6), and these results
indicate a pharmacologic or irritant-mediated bronchoconstriction mechanism for
acute exposure to this compound. No effect on post-exposure baseline pulmonary
function (saline challenge) was found with the exposure regimens used in this study
and no differences in dermal sensitivities to sodium hexachloroplatinate(IV) was
observed in any of the groups. When compared on the basis of monkey to human
minute volume ratio a concentration of 200 mg/m3 (4 h/day biweekly for 12 weeks),
according to the authors, result in an equivalent exposure of 3 to 4 times of that to
which a worker would be exposed in 1 week at the air level 2 mg/m3 (17).
In further experiments in male Cynomolgus monkeys, combined inhalation expo-
sure of 200 mg/m3 ammonium hexachloroplatinate(IV) (MMAD 1.07 mm) and
1 ppm ozone 6 h/day, 5 days per week for 12 weeks was shown to significantly
reduce (difference in postexposure and preexposure values) the concentration of
platinum salt (sodium hexachloroplatinate(IV))  and methacholine necessary to
increase average pulmonary flow resistance (RL) by 200%, indicating that combined
exposure increased both specific and nonspecific bronchial hyperreactivity more
often than did exposure to either ozone or the Pt salt alone. Some animals with
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combined exposure exhibited extremely elevated RL values and haemoptysis
(expectoration of blood) after challenge with the most dilute solutions. Combined
exposure also significantly increased the incidence of positive skin tests to platinum
(intracutaneous test) when compared with exposure to platinum or ozone alone. The
baseline pulmonary function (saline challenge) was not significantly affected by the
exposure regimens and exposure to ammonium hexachloroplatinate(IV) or ozone
alone (mean values) had no significant effects on postexposure Pt or methacholine
reactivity (16).
In a study in female Hooded Lister rats (103) conjugation of ammonium tetra-
chloroplatinate(II) with ovalbumin produced conjugates (administered with adju-
vant) capable of inducing IgE antibody (PCA challenge, RAST), whereas no speci-
fic IgE antibody was induced in animals given free platinum salt (1 mg-1 mg via
various routes including intratracheal). Significant cross reactivity (PCA-tests) in
Hooded Lister rats immunized with ovalbumin-ammonium tetrachloroplatinate,
between ammonium tetrachloroplatinate(II), ammonium hexachloroplatinate(IV) and
the conjugated tetrachloroplatinate was found by the same authors, while there was
no cross-reactivity with the compounds cesium trichloronitroplatinate(II), cisplatin,
potassium tetracyanoplatinate(II) and tetraammineplatinum(II) chloride (104). In a
later study (105) repeated injections of ammonium tetrachloroplatinate(II) (100
mg/kg bw three times a week for 3 weeks; adjuvant) to female Hooded Lister rats
immunised with antigen (OVA) was shown to give elevated levels of total IgE as
well as raised RAST levels (specific IgE antibody directed against ovalbumin).
In a study for US EPA (157) the potential for platinum(IV) sulphate and plati-
num(IV) chloride to elicit skin sensitisation was investigated in a number of labora-
tory animals. No allergic induction was shown, when platinum(IV) sulphate was
repeatedly injected (0.05-0.35 mg/ml subcutaneously or intravenously) into albino
rabbits, albino guinea pigs and white Swiss mice or platinum(IV) sulphate paste
was repeatedly applied to rabbits and guinea pigs (0.1-0.25 g/application). The
animals were tested by intradermal skin test (rabbits, guinea pigs) and footpad test
(mice). When guinea pigs were skin tested 14 days after the last subcutaneous
injection of platinum(IV) chloride (1.5-4.5 mg/ml) the skin test reactions were also
found to be negative. Furthermore, platinum-albumin complexes injected sub-
cutaneously at various concentrations (and later skin tested intradermally) failed to
induce an allergic response to platinum in rabbits and guinea pigs (157). However,
no positive control substances were used to demonstrate the effectiveness of the test
procedures.
Immunogenicity of Pt salts was demonstrated in mice by means of the popliteal
lymph node (PLN) assay. There were differences in the degree of response between
the various strains used on the study (BALB/c, DBA/2, C57BL/6, B10.S,
C3H/He, NMRI +/nu, NMRI, NMRI nu/nu) and it was shown that mice deficient
of T-lymphocytes completely failed to respond. A single subcutaneous injection of
dissolved hexachloroplatinates (Na2(PtCl6), (NH4)2(PtCl6)) without adjuvant
induced a dose-dependent lymph node activation (determined by an increase in both
PLN weight and cellularity) in mice of strain C57BL/6. Significant PLN reactions
were induced at doses about 20-160 mg/animal (45-360 nmol/animal; about 1-8
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mg/kg bw) and peak reactions were obtained around day 6 after administration of
about 40-80 mg/animal (90-180 nmol per animal; about 2-4 mg/kg bw). Mice sensi-
tised to (PtCl6)
2- mounted an enhanced response upon local restimulation with
suboptimal doses of the same, but not unrelated compounds, indicating a specific
secondary response (about one fifth of the primary dose proved to be sufficient for
elicitation of a secondary response with Na2(PtCl6) = 36 nmol/animal; 16Êmg/
animal; about 0.8 mg/kg bw) (143). Apart from hexachloroplatinates, equimolar
amounts of sodium tetrachloroplatinate(II) elicited a strong primary PLN response.
Lower but still significant PLN indices were obtained with cisplatin, which had to
be tested at a lower dosage due to its limited solubility (strains C57BL/6 or BALB/c
were used for the various Pt compounds) (143). In a modified test system in
C57BL/6 mice 3x2 mg sodium hexachloroplatinate(IV)/mouse was injected weekly
(sc or ip) for 20 weeks or 0.2 mg sodium hexachloroplatinate(IV)/mouse/week was
dripped in the nose for 20 weeks and spleen cells from treated animals were then
injected subcutaneously (up to 22 weeks after cessation of treatment) into untreated
animals. 24 hours later a suboptimal dose of the compound (18 nmol; 8 mg/animal;
about 0.4 mg/kg bw) was injected (untreated mice) and it was shown that a PLN
reaction was elicited and that the nasal route of administration had been the most
efficient in inducing immunity (144, 145). Unpublished results (cited in 144)
concerning platinum(IV) chloride, platinum(II) chloride, platinum(IV) oxide and
platinum metal showed that the soluble Pt compound caused PLN reactions, but as
platinum(IV) chloride is not very stable in solution it was considered that the reac-
tions was caused by formed complexes. The insoluble Pt compounds could not be
evaluated in this test.
Ammonium tetrachloroplatinate(II) has been tested in the guinea-pig maximization
test (GPMT) in albino Dunkin-Hartley guinea-pigs and a local lymph node assay
(LLNA) in CBA/Ca mice to predict the skin sensitisation potential. The compound
was classified as an extreme sensitiser in GPMT (intradermal induction injections
0.05%; induction patch 5%, challenge patch 1%) and found to be positive (gave a
proliferative response) in LLNA (the test substance was assayed at three concentra-
tions; topical application of 2.5, 5 or 10%) (9).
10.2. Effects of single exposure
The acute toxicity of platinum depends on the compound, the dose and the route of
administration. Generally the toxicity of platinum compounds is much higher by
intraperitoneal or intravenous administration than by oral administration. There are
insufficient data, however, concerning inhalation exposure (50, 63). Within a given
class of Pt compounds the acute toxicity follows the water solubility to some degree
and thus, water soluble compounds usually are more toxic than insoluble ones (49,
50, 63, 108). Some LD50 values for rats are tabulated in Table 11. In a study in rat,
the pretreatment with a lower dose of platinum(IV) chloride, 48 hours before a
higher generally lethal dose (113 mmol/kg) of the compound, markedly increased
the survival (51).
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Platinum metal appears to have low acute toxicity at oral administration, but the
highly dispersed powder, although insoluble in water, might be absorbed to some
extent from the gastrointestinal tract. When orally administered to rats as fine dust
(1-5 mm; doses not specified) necrotic changes in the gastrointestinal epithelium,
granular dystrophy of hepatocytes, and signs of swelling in the epithelium of the
convoluted renal tubules was observed in a poorly reported russian study (133).
The highest dose given (25167 mg/kg according to personal communication to
IPCS) was not lethal.
Few details on the clinical signs of acute toxicity of platinum salts are given in the
literature. However, in an unpublished report (Degussa, 1989a, cited in 63) signs
of poisoning with ammonium tetrachloroplatinate(II) are described and include
diarrhoea, clonic convulsions, laboured respiration and cyanosis. Hexachloro-
platinic(IV) acid was shown in one study (171) to be highly nephrotoxic in male
F344 (Fischer CDF) rats. Rats died of renal failure, hypocalcemia, and hyper-
kalemia after a singel intraperitoneal injection of 40-50 mg/kg. The tubular necro-
tizing lesions involved the entire renal cortex. Severe histopathological lesions were
also observed in thymus (171). When platinum(IV) sulphate was administered
intragastrically as a single dose, at the LD25 level (213 mg Pt/kg), to mice general
activity expressed as open field behaviour (ambulations) was significally depressed,
while exploratory behaviour was not affected (85).
Table 11. Some LD50 values* after peroral (po) or intraperitoneal (ip) administration
of platinum compounds to rats
Compound Route LD50
(mg/kg)
LD50
(mg Pt/kg)
Platinum (IV) oxide po >8000c, >3405a >6900c, >2926a
Platinum(II) chloride po >2000c, >1330a >1400c, >975a
Platinum(II) chloride ip 670c 490c
Platinum(IV) chloride po 240c 136c
Platinum(IV) chloride ip 38c 22c
Platinum(IV) sulphate (4H2O) po 1010
a 430a
Platinum(IV) sulphate (4H2O) ip 138
c-184c, 310c-312a 59c-78c, 132c-133a
Hexachloroplatinic(IV) acid ip 40b-50b 15**b-19**b
Ammonium tetrachloroplatinate(II) po 125-212 65-111
Ammonium hexachloroplatinate(IV) po 200 88
Potassium tetrachloroplatinate(II) po 50-200 23-94
Potassium tetracyanoplatinate(II) po >2000 >1770
Sodium hexachloroplatinate(IV) po 25-50 11-21
Sodium hexahydroxyplatinate(IV) po 500-2000 284-1137
Tetraammineplatinum(II) chloride po >15000 >8759
Diamminedinitroplatinum(II) po 5000, >5110 3037, >3104
*The LD50 values are taken from unpublished reports cited in 63 unless otherwise is stated. Other
references used are a50, b171 and c49. If the LD50 value is expressed as mg/kg as well as mg Pt/kg
in the reference both values are used in the table, otherwise the mg Pt/kg-values have been calcula-
ted from the given LD50 values.
**Counted as the hexahydrate.
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10.3. Effects of repeated exposure
The effects of platinum compounds after repeated exposure have been studied
mainly by the use of other routes than inhalation and include decrease in weight gain
and effects on kidneys.
A reduction in weight gain by about 20%, probably related to a decrease in feed
and fluid consumption, was observed in male Sprague-Dawley rat during the first
week when 550 mg/L (1.63 mmol/L) of platinum(IV) chloride was added to the
drinking-water for 4 weeks (total intake of approximately 250 mg Pt/rat or about
43 mg Pt/kg bw/day). A concentration of about 180 mg/L (0.54 mmol/L; total
intake 60 mg Pt/rat or about 10 mg Pt/kg bw/day) for 4 weeks did not affect the
normal weight gain (50). An increase in kidney weight by about 6-10% (p<0.05)
was also noted at the higher dose level, when the compound was administered for 4
weeks, while the weights of the five organs investigated (liver, kidney, spleen,
heart, testes) were not affected when the same dose was given for 8 days or at a
concentration of 180 mg/L (0.54 mmol/L) for 29-30 days (total intake approxi-
mately 60 mg Pt/rat in the two latter experiments; about 60 and 10 mg Pt/kg
bw/day) (50). When platinum(IV) sulphate (tetrahydrate) was administered at a
concentration of about 750 mg/L (1.63 mmol/L; totally approximately 60 mg Pt/rat
or 59 mg Pt/kg bw/day) in the drinking fluid for about 1 week the weight gain was
reduced, while the organ weights were not significantly affected (50). In studies
with other platinum compounds (49, 51, 100) it was shown, that platinum(IV)
oxide had no effect in male Sprague-Dawley rats on weight gain during each of 4
weeks, when present in the feed at a level of 6.8 g/kg (29.8 mmol/kg diet; total dose
4.9 g Pt/rat, corresponding to about 700 mg Pt/kg bw/day), while there was a
decrease in weight gain (and water consumption) in albino rats (Charles River CD-
1-strain) given drinking water containing 235 mg/L (ppm) or 470 mg/L (ppm)
potassium tetrachloroplatinate(II) for 23 days.
No influence on body weight gain or food consumption was noticed in a study in
male Sprague-Dawley rats, when platinum was added in the diet in the form of
platinum(II) chloride or platinum(IV) chloride in amounts of up to 50 mg Pt/kg diet
for 4 weeks (total average intake of platinum up to 21 mg/rat or on average 5 mg
Pt/kg bw/day). In the case of platinum(IV) chloride there was a tendency towards
decrease in the counts of erythrocytes as well as haematocrit with increasing
amounts of the compound (at the highest dose level about 13%), whereas the
volume of erythrocytes as well as haemoglobin content were not influenced. A
significant increase of creatinine content in plasma also was shown at the highest
dose level (platinum(IV) chloride) (130). When female Sprague-Dawley rats were
fed a diet containing either platinum(IV) chloride or platinum metal in a concentra-
tion of 0.1, 0.5, 1.0, 50 and 100 mg Pt/kg diet (ppm) respectively, four weeks
before pregnancy to twentieth day of gestation, there were no changes in haemato-
logical values (haemoglobin content, haematocrit, count and volume of erythro-
cytes) after intake of platinum(IV) chloride, while intake of platinum metal at the
100 ppm level (totally 88 mg Pt/rat or around 7 mg Pt/kg bw/day) led to a signifi-
cant increase in red blood cell count. Growth rate and organ weights (liver, kidney
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and spleen) of the mothers were uninfluenced of the intake of platinum(IV) chloride
or platinum metal (18, 19). In two other studies (5, 6) no clinical signs of toxicity
and no effect on feed intake, growth, haemoglobin content of blood, haematocrit or
count and volume of erythrocytes was observed in male Sprague-Dawley rats after
administration of up to 50 mg/kg (ppm) platinum metal powder in the diet for
4 -12 weeks (particle size 0.5-150 mm; 6).
No overt ill effects and no significant differences in body weights were observed
for male Cynomolgus monkeys exposed by inhalation to 177 mg/m3 ammonium
hexachloroplatinate(IV) or 208 mg/m3 ammonium hexachloroplatinate(IV) and
1 ppm ozone for 12 weeks (6 h/day, 5 days per week; MMAD 1 mm) (16). How-
ever, the study was designed to detect differences in immunologic parameters and
effects in the airways.
Chronic intoxication in rats after inhalation of 18.6 mg/m3 ammonium chloro-
platinate (no exposure time is given) was reported in a Russian study (133) and
included reduction in body mass, decrease in the content of haemoglobin in blood,
decrease in cholinesterase in blood, increase in acid phosphatase, alkaline phospha-
tase, alanine aminotransferase and aldolase, disturbances in carbohydrate and lipid
metabolism, reduced concentrating capacity of the kidney, increased concentration
of urea in blood and morphological changes reminiscent of glomerulonephritis. At
the exposure level 4.5 mg/m3 the effects were reported to be poorly expressed and
reversible (disappeared after 30 days of recovery). However, the study is only
described in brief and there are shortcomings (e.g. no values for exposed versus
unexposed animals are presented and the contribution of platinum versus palladium
to the toxic effects are difficult to interpret) and thus the reliability of the results are
unclear.
10.4. Mutagenicity and genotoxicity
The antineoplastic agent cisplatin (cis-dichlorodiammineplatinum(II)) has been
shown to bind to DNA and to be mutagenic in vitro and in vivo (61, 62, 74, 102,
155). Mutagenic activity has been found in vitro with other Pt compounds too,
especially complexes with the same square-planar configuration of cis-PtN2X2 as
cisplatin (166). Cytotoxicity is a common property of many Pt(II) and Pt(IV)
complexes and some novel ammine/amine platinum(IV) dicarboxylates have been
found to be at least 100 times more cytotoxic than cisplatin in vitro (74, 132). At
least part of the increased cytotoxicity of the dicarboxylates over cisplatin may be
attributable to an increased intracellular accumulation due to enhanced lipophilicity
(74).
10.4.1. Effects in bacteria
The influence of molecular structure on mutagenicity was examined in a study (166)
using Salmonella typhimurium TA 98 and TA 100. Seven of the 15 platinum com-
pounds tested (0.8-100 nmol/plate) were considered direct mutagens as their muta-
genicity was not dependent on metabolic activation by S9 mix. Strong mutagenicity
and high toxicity for both bacterial strains were exhibited by cisplatin and three
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other compounds with a molecular structure similar to cisplatin (cis-PtN2X2),
whereas relatively strong mutagenicity (toxicity was also observed) was noticed
with the complex salt chlorotriammineplatinum(II) tetrachloroplatinate(II) (Cleve«s
salt). The charged compounds potassium tetrachloroplatinate(II) and hexachloro-
platinic(IV) acid  (hexahydrate) showed weak mutagenicity, the latter only after
metabolic activation (TA 98). Cis-potassium dichlorodinitroplatinate(II) also
showed weak mutagenic activity, but only without metabolic activation (TA 98).
Potassium hexakis(thiocyanato) platinate(IV) and potassium
hexabromoplatinate(IV) showed toxicity in both strains but mutagenicity was not
observed due to killing. Among the compounds not showing mutagenic activity
were: tetraammineplatinum(II) chloride, cis-dinitrodiammineplatinum(II), potassium
tetranitroplatinate(II) dihydrate and barium cyanideplatinum(II) tetrahydrate (166).
Similarly, it was found in earlier studies in Salmonella typhimurium TA 100, that
the charged platinum compounds (e.g. potassium tetrachloroplatinate(II), potassium
amminetrichloroplatinate(II), tetraammineplatinum(II) chloride, chlorotriammine-
platinum(II) chloride) generally had low mutagenicity, whereas neutral compounds
with a cis-PtN2X2 structure had definite mutagenic properties (79, 80). Cisplatin
was the by far most mutagenic of the compounds tested (79, 80). However, an
obvious mutagenic activity of potassium amminetrichloroplatinate(II) and ammo-
nium amminetrichloroplatinate(II) was found in one study (121) on different strains
of Salmonella typhimurium (TA 92, TA 94, TA 98, TA 100, TA 1535,
TA 1537, TA 1538) and in an unpublished study (cited in 56) tetraammineplati-
num(II)chloride was found to be mutagenic in Salmonella strain TA 1537 (tested in
TA 98, TA 100, TA 1535, TA 1537, TA 1538). When different platinumchloro-
ammine complexes were investigated in a study in Salmonella typhimurium in order
to find a correlation between chemical reactivity and biological activity it was found,
that a structure of a neutral complex creating a very labile ligand gave more toxic but
less mutagenic complexes than cisplatin (28).   
In a study using five strains of Salmonella typhimurium (TA 98, TA 100,
TA 1535, TA 1537, TA 1538) and two strains of Escherichia coli (B/r WP2 try,
WP2 hcr try) ammonium hexachloroplatinate(IV) and platinum(IV) chloride were
stated to be potent mutagens. Ammonium hexachloroplatinate(IV) was found to
induce mutations in one strain of E. coli and in Salmonella typhimurium TA 98,
whereas platinum(IV) chloride was mutagenic only in Salmonella typhimurium TA
98 (concentrations not given). Hexachloroplatinic(IV) acid was not positive in these
assays. The same authors showed that hexachloroplatinic(IV) acid (0.01 mol/L),
ammonium hexachloroplatinate(IV) (0.1 mol/L) and platinum(IV) chloride (0.001
mol/L) were strongly genotoxic in the Bacillus subtilis rec-assay (71).
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Table 12. Genetic activity of some platinum compounds in short-term tests in vitro
Compound Indicator cell With or
without S9
Doses tested Genetic
activity
Ref
Platinum(II)
chloride
mouse lymph.
cell line L5178Y
- 0-800 mmol/L - 137
Platinum(IV)
chloride
S. typhimur. TA 98
S. typhimur. TA 100
-
-
not given
not given
+
-
71
71
S. typhimur. TA 1535 - not given - 71
S. typhimur. TA 1537 - not given - 71
S. typhimur. TA 1538 - not given - 71
E. coli B/r WP2 try - not given - 71
E. coli WP2 hcr try - not given - 71
B. subtilis H17, M45 - 0.001 mol/L + 71
Saccharom. F 51 - 0-0.3 mmol/L + 48
V79 cells - 0-15 mmol/L + 72
CHO-S cells - 0-70 mmolL + 159
CHO-AUXB1 cells - 0-25 mmol/L + 159
SHE cells
mouse lymph. cell line
L5178Y
-
-
0-0.12 mmol/L
25-150 mmol/L*
+
+
26
137
Platinum(IV)
sulphate
CHO-S cells
CHO-S cells
CHO-AUXB1 cells
-
-
-
0-160 mmol/L
up to 550 mmol/L
0-150 mmol/L
+
+
+
158
151
161
Hexachloro- S. typhimur. TA 98 - not given - 71
platinic(IV) acid S. typhimur. TA 98 + 0.8-100 nmol/plate + 166
S. typhimur. TA 98 - 0.8-100 nmol/plate - 166
S. typhimur. TA 100 - not given - 71
S. typhimur. TA 100 + 0.8-100 nmol/plate - 166
S. typhimur. TA 100 - 0.8-100 nmol/plate - 166
S. typhimur. TA 1535 - not given - 71
S. typhimur. TA 1537
S. typhimur. TA 1538
-
-
not given
not given
-
-
71
71
E. coli B/r WP2 try - not given - 71
E. coli WP2 hcr try - not given - 71
B. subtilis H17, M45 - 0.01 mol/L + 71
Ammonium
hexachloro-
platinate(IV)
S. typhimur. TA 98
S. typhimur. TA 100
S. typhimur. TA 1535
-
-
-
not given
not given
not given
      +
not concl.
not concl.
71
71
71
S. typhimur. TA 1537 - not given - 71
S. typhimur. TA 1538 - not given - 71
E. coli B/r WP2 try - not given - 71
E. coli WP2 hcr try - not given + 71
B. subtilis H17, M45 - 0.1 mol/L + 71
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Table 12. Cont.
Compound Indicator cell With or
without S9
Doses tested Genetic
activity
Ref
Potassium tetra- S. typhimur. TA 98 + 0.8-100 nmol/plate + 166
chloroplatinate(II) S. typhimur. TA 98 - 0.8-100 nmol/plate + 166
S. typhimur. TA 100 + 0.8-100 nmol/plate + 166
S. typhimur. TA 100 - 0.8-100 nmol/plate + 166
S. typhimur. TA 100 not given 150 mg/plate** + 79
Saccharom. cerevisiae - 42 mg/ml*** + 153
CHO-S cells - 40 mmol/L**** - 158
CHO-AUXB1 cells - 0-103 mmol/L + 160
CHO-K1-BH4 cells - 0-65 mmol/L +/- 57,68
Potassium hexa-
chloroplatinate(IV)
CHO-S cells
CHO-S cells
-
-
up to 220 mmol/L
10 mmol/L
60 mmol/L****
+
+
151
158
CHO-AUXB1 cells - 0-103 mmol/L + 160
cis-Potassium
dichlorodinitro-
platinate(II)
S. typhimur. TA 98
S. typhimur. TA 98
S. typhimur. TA 100
+
-
+
0.8-100 nmol/plate
0.8-100 nmol/plate
0.8-100 nmol/plate
-
+
-
166
166
166
S. typhimur. TA 100 - 0.8-100 nmol/plate - 166
Potassium tetra-
nitroplatinate(II)
dihydrate
S. typhimur. TA 98
S. typhimur. TA 98
S. typhimur. TA 100
S. typhimur. TA 100
+
-
+
-
0.8-100 nmol/plate
0.8-100 nmol/plate
0.8-100 nmol/plate
0.8-100 nmol/plate
-
-
-
-
166
166
166
166
Barium cyanide-
platinum(II) tetra-
hydrate
S. typhimur. TA 98
S. typhimur. TA 98
S. typhimur. TA 100
S. typhimur. TA 100
+
-
+
-
0.8-100 nmol/plate
0.8-100 nmol/plate
0.8-100 nmol/plate
0.8-100 nmol/plate
-
-
-
-
166
166
166
166
Ammonium
amminetrichloro-
platinate(II)
S. typhimur. TA 92
S. typhimur. TA 94
S. typhimur. TA 98
S. typhimur. TA 100
-
-
-
-
12.5-50 mg/well
12.5-50 mg/well
12.5-50 mg/well
12.5-50 mg/well
+
+
+
+
121
121
121
121
S. typhimur. TA 1535 - 12.5-50 mg/well + 121
S. typhimur. TA 1537 - 12.5-50 mg/well + 121
S. typhimur. TA 1538 - 12.5-50 mg/well - 121
Potassium
amminetrichloro-
platinate(II)
S. typhimur. TA 92
S. typhimur. TA 94
S. typhimur. TA 98
S. typhimur. TA 100
-
-
-
-
25-100 mg/well
25-100 mg/well
25-100 mg/well
25-100 mg/well
+
+
+
+
121
121
121
121
S. typhimur. TA 100 not given 10 mg/plate** + 79
S. typhimur. TA 1535 - 25-100 mg/well + 121
S. typhimur. TA 1537 - 25-100 mg/well + 121
S. typhimur. TA 1538 - 25-100 mg/well + 121
CHO-K1- BH4 cells - 0-50 mmol/L + 57,68
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Table 12. Cont.
Compound Indicator cell With or
without S9
Doses tested Genetic
activity
Ref
Chlorotriammine
platinum(II) tetra-
chloroplatinate(II)
(Cleve«s salt)
S. typhimur. TA 98
S. typhimur. TA 98
S. typhimur. TA 100
S. typhimur. TA 100
+
-
+
-
0.8-100 mmol/plate
0.8-100 mmol/plate
0.8-100 mmol/plate
0.8-100 mmol/plate
+
+
+
+
166
166
166
166
Chlorotriammine
platinum(II)
chloride
S. typhimur. TA 100
CHO-K1- BH4 cells
not given
-
50 mg/plate**
0-360 mmol/L
+
+
79
57,68
Tetraammine-
platinum(II)
chloride
S. typhimur. TA 98
S. typhimur. TA 98
S. typhimur. TA 98
S. typhimur. TA 100
S. typhimur. TA 100
S. typhimur. TA 100
S. typhimur. TA 100
S. typhimur. TA 1535
S. typhimur. TA 1537
S. typhimur. TA 1537
S. typhimur. TA 1538
CHO-K1- BH4 cells
+
-
not given
+
-
not given
not given
not given
+
-
not given
-
0.8-100 nmol/plate
0.8-100 nmol/plate
not given
0.8-100 nmol/plate
0.8-100 nmol/plate
not given
>250 mg/plate**
not given
not given
not given
not given
0-6600 mmol/L
-
-
-
-
-
-
+
-
+
+
-
-
166
166
56
166
166
56
79
56
56
56
56
57,68
cis-Dinitro-
diammine-
platinum(II)
Dinitrodiammine-
platinum(II)
S. typhimur. TA 98
S. typhimur. TA 98
S. typhimur. TA 100
S. typhimur. TA 100
mouse lymph.
cell line L5178Y
+
-
+
-
-
0.8-100 nmol/plate
0.8-100 nmol/plate
0.8-100 nmol/plate
0.8-100 nmol/plate
0-200 mmol/L
-
-
-
-
-
166
166
166
166
137
*the doses are not clearly given
**maximal dose in the reversion test within the linear dose-response curve (all doses not given)
***maximal efficient dose (all doses not given)
****all doses not given
+/- marginal
10.4.2. Effects in yeast
In a study on growing yeast cells (Saccharomyces strain F51 and 2200) platinum(IV)
chloride as well as cisplatin was found to strongly inhibit DNA, RNA and ribosome
synthesis. A comparison of the concentrations required to produce a 50% inhibition
showed that platinum(IV) chloride was more efficient in inhibiting DNA synthesis
than cisplatin (I50 0.2 mmol/L versus 0.42 mmol/L), while cisplatin was more
efficient in inhibiting cell growth (I50 0.6 mmol/L versus 1.1 mmol/L) (48).
In a system to detect chromosome number abnormalities occurring during meiosis
in Saccharomyces cerevisiae a weak induction of diploid spores was found with
potassium tetrachloroplatinate(II) (maximal efficient dose 42 mg/ml) (153).
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10.4.3. Effects in mammalian cells
Six square-planar platinum(II)chloroammines with the charge ranging from
+2 {[Pt(NH3)4]
+2} to -2 {[PtCl4]
-2} and the number of reactive sites varying from
4 (tetrachloride) to 0 (tetraammine) was tested in a structure-mutagenicity study with
the CHO/HGPRT (hypoxanthine-guanine phosphoribosyl transferase)-system.
Three of the compounds exhibited mutagenic activity and among them cisplatin was
the most potent. Based on the slope of the linear portion of the mutation induction
curve, the approximate relative mutagenic activity of cisplatin, potassium trichlor-
ammineplatinate(II) and chlorotriammine platinum(II) chloride was 100:8:0.3. The
mutation frequency of potassium tetrachloroplatinate(II) was less clear, but judged
to be marginal, whereas no mutagenicity was found with tetraammineplatinum(II)
chloride. The relative cytotoxicity of the compounds followed the same order as the
mutagenicity (57, 68).
A dose-dependent increase in mutant frequency was found with cisplatin, plati-
num(IV) sulphate and platinum(IV) chloride in CHO-S cells using 8-azaguanine
(8-AG) for mutant selection, following a 20 h exposure (158, 159). Cisplatin was
calculated by the authors to be 38-fold more mutagenic than platinum(IV) sulphate.
Identical 20 h exposures to varying amounts of e.g. potassium tetrachloro-
platinate(II) and potassium hexachloroplatinate(IV) did not induce 8-AG mutants.
However, an increased exposure period (10-25 population doublings) potassium
hexachloroplatinate(IV) (10 mM) was weakly mutagenic (158). None of the com-
pounds were as effective as cisplatin at inhibiting cell growth (I50=0.9 mM).
In studies on CHO AUXB1 cells (159, 160, 161) a dose-dependent increase
above the spontaneous revertant frequency (at concentrations where the cell survival
remains high), reflecting mutations involving the FPGS (folylpolyglutamate
synthetase) gene locus, was induced after 20-22 h exposure with cisplatin,
platinum(IV) sulphate, platinum(IV) chloride, potassium tetrachloroplatinate(II) and
potassium hexachloroplatinate(IV). Platinum(IV) sulphate was about 50 times less
mutagenic than cisplatin on a concentration basis (161).
Cellular resistance to the toxic effects of potassium hexachloroplatinate(IV)
(220 mM) and platinum(IV) sulphate (550 mM) (quantitated by comparing plating
efficiencies), interpreted by the authors to be a result of mutation and selection, was
induced separately in cultured CHO-S cells by continuous exposure to the com-
pounds for 5 and 4 months, respectively (151).
Induction of mutation by platinum(IV) chloride was measured utilizing the
HGPRT locus in V79 cells. Treatment with 15 mM of platinum(IV) chloride in-
creased the mutation frequency at rates of around 7 times control rates (72).
In a mutagenic test with mouse lymphoma cells line L5178Y cisplatin and plati-
num(IV) chloride, but not platinum(II) chloride and dinitrodiammineplatinum(II),
were found to be  mutagenic at the thymidine kinase locus. Cisplatin was more
potent as a mutagen than platinum(IV) chloride (137).
Platinum(IV) chloride (0.03-0.12 mM) was found to significantly enhance viral
transfomation of Syrian hamster embryo cells (26).
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10.4.4. Effects in vivo
A significant increase in recessive sex-linked lethal mutations was found after
feeding of  1.5x10-3M platinum(IV) chloride solution for 48 hours or 3x10-4M
platinum(IV) chloride solution for 72 hours to adult males of fruitfly (Drosophila
melanogaster) (179). In two other studies (unpublished reports, cited in 56)
tetraammineplatinum(II) chloride and potassium tetrachloroplatinate(II) did not
induce any increase in the frequency of sex-linked recessive lethal mutations in male
fruitfly up to doses which produced about 50% lethality, but without causing
sterility.
In micronucleus studies (unpublished reports, cited in 56) tetraammine-
platinum(II) chloride and potassium tetrachloroplatinate(II) were administered as a
single oral dose to male and female mice and bone marrow was sampled 24 hours
later. No effect was seen in the numbers of micronucleated polychromatic
erythrocytes (PCE) or on (PCE)/normochromatic erythrocytes ratio. However, the
highest doses used (5000 mg/kg: Pt(NH3)4Cl2; 150 mg/kg: K2PtCl4) resulted in
deaths. The clastogenic effects of these two compounds were also investigated in
male and female Chinese hamsters, which received oral gavage doses daily for 5
days. No effect was observed on the frequency of aberrant metaphases following
treatment with either substance. Tetraammineplatinum(II) chloride produced a dose-
related decrease in body weight and one animal in the highest dose group (1000
mg/kg) died; there was also some indication of a reduction in the mitotic index of
bone marrow cells in a preliminary study, which included main-test doses. For
potassium tetrachloroplatinate(II) there was a general reduction in the mitotic index
(2.9-3.1%) in the treated animals compared to controls (4.6%) (unpublished
reports, cited in 56). Overall it was concluded, that tetraammineplatinum(II)
chloride and potassium tetrachloroplatinate(II) did not induce any mutagenic effects
in the bone marrow cells of mouse or hamster.
It can be concluded, that most of the described complexes/salts of platinum are
genotoxic/mutagenic in vitro (Table 12), but there generally is a lack of information
from in vivo studies.
10.5. Carcinogenic effects
No relevant studies on the carcinogenicity of platinum and platinum compounds,
except for cisplatin and certain related compounds, have been found. Cisplatin has
been shown to cause extensive DNA damage at low doses and there is sufficient
evidence for carcinogencity  of cisplatin (cis-dichlorodiammineplatinum(II)) in ani-
mals (61, 62). Some other antitumor cis-platinum(II) coordination complexes
shown to be carcinogenic in rodents are cis-dichlorobis(cyclopentylamine)-
platinum(II) and cis-dichlorobis(pyrrolidine)-platinum(II) (80).
10.6. Reproductive and developmental effects
Influences of alimentary platinum(IV) chloride and platinum metal on reproduction
were studied in female Sprague-Dawley rats (18). The animals were fed a diet con-
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taining 0.1, 0.5, 1.0, 50 and 100 mg Pt/kg diet (ppm) either of platinum(IV)
chloride or platinum metal for four weeks before pregnancy to twentieth day of
gestation. Neither the average wet weight of foetus and placenta nor the average
number of normal and absorbed foetus were dependent on the Pt-ingestion of the
mothers. Thus, no increase in external malformations were seen. When
platinum(IV) chloride or platinum(II) chloride was given in concentrations up to
100 mg Pt/kg in the diet to lactating rats (21 days) no influence on the weight of the
offspring or on count and volume of erythrocytes, haematocrit and haemoglobin in
maternal blood/blood of offspring was found (77).
Effects on the development of offspring were investigated in female Swiss ICR
mice exposed to platinum(IV) sulphate or sodium hexachloroplatinate(IV) during
pregnancy or lactation (30). A single intragastric dose of platinum(IV) sulphate
(200 mg Pt/kg) or a single subcutaneous dose of sodium hexachloroplatinate(IV)
hexahydrate (20 mg Pt/kg) at the LD1 level was administered on day 7 or 12 of
gestation or on day 2 post-partum. The pups were cross-fostered to treated or
untreated dams at birth. Rate of growth and gross activity of the neonates were
assessed. On day 60-65 postpartum open-field behavior (ambulation and rearing),
rotarod performance, and passive avoidance learningwere investigated in the adult
offspring. The predominant effect of maternal administration of platinum(IV)
sulphate on day 7 and 12 of gestation was reduced offspring weight. This effect
continued through day 45 postpartum. Type of foster-mother exposure also had a
significant effect on offspring weight. For example on day 45 postpartum, no
matter what their gestational history, pups reared by foster mothers exposed to
platinum during gestation weighed less than pups reared by control mothers. In the
platinum(IV) sulphate lactational study (treatment on day 2 postpartum), pups
reared by mothers receiving platinum(IV) sulphate were less active than pups reared
by control mothers. The effects on neonatal and adult offspring of maternally
administered sodium hexachloroplatinate(IV) were limited to exposure on day 12 of
gestation and were expressed in some of the tests as a reduced activity level.
Platinum(IV) chloride, injected by the intratesticular route in albino rats (single
dose; 0.08 mmole/kg bw or 27 mg/kg bw) or by the subcutaneous route in Swiss
mice (30 days; total dose 0.08 mmole/kg bw or 27 mg/kg bw), was shown to cause
a large reduction in testis weight. Total testicular necrosis and destruction of all
spermatozoa was seen within two days in rat, while spermatogenic arrest at the pri-
mary spermatocyte or spermatogonial stages (without affecting the interstitium) was
found in mouse (70). When strips of platinum metal was tested in vitro (incubation
time 2-5 h) a weak inhibition of human sperm motility was found in one study (75).
In a later study (52) no significant reduction in motility of human spermatozoa was
shown (platinum metal; in vitro), but if the incubation had been prolonged beyond
three hours, a small spermicidal effect may have been observed in this study.
10.7. Other studies
The local action of the sodium hexachloroplatinate(IV) has been studied in guinea-
pig. The injection of 0.2 ml of a 10-4 g/ml solution into the abdominal skin was fol-
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lowed by an increased capillary permeability, demonstrated by showing the local
accumulation of Evans Blue (136). When skin testing (Evans blue dye iv and after
15 minutes serial dilutions of 1x10-7 to 1x10-3 g/ml solutions of Na2PtCl6 intra-
dermally) was performed on male Cynomolgus monkeys before and after 12-week
exposure regimens (biweekly) with sodium hexachloroplatinate(IV) (200 mg/m3,
2000 mg/m3 or 1 ml of 20 mg/ml Na2PtCl6 percutaneously) positive dermal bluing
reactions were obtained with 12 of 19 animals at dilutions of 10-5 g/ml. However,
the results showed no change in the extent of dye leakage before and after the expo-
sure (17).
Enzymes regulating the haeme pathway in liver and kidney was affected in male
Sprague-Dawley rats, when potassium hexachloroplatinate(IV) or potassium
tetrachloroplatinate (II) was given subcutaneously as a single dose of 60 mg/kg
(125 mmol/kg bw) and 52 mg/kg (125 mmol/kg bw), respectively (86, 117). Inter-
action with the degradation of haeme via the enzyme haeme oxygenase (transient
depression followed by stimulation) was noticed in one study (86) and it was
shown, that microsomal haeme and cytochrome P450 contents had diminished
substantially in liver and kidney when the activity of haeme oxygenase was highly
elevated (at 16 h). Furthermore, a change in liver content of glutathione (GSH)
(depletion followed by a rebound) was shown in the study after administration of
potassium hexachloroplatinate(IV) and when Pt2+ and Pt4+ was administered as a
complex with glutathione their abilities to perturb haeme metabolism (e.g. haeme
oxygenase activity) was blocked (86). The biosynthesis of haeme was also affected
in different ways after administration of potassium hexachloroplatinate(IV). The
activity of delta-aminolevulinic acid synthetase (ALAS) in the liver and kidney was
decreased for about 12 h and then increased (86, 117). Reduced activities of other
enzymes regulating haeme biosynthesis in the kidney (delta-aminolevulinic acid
dehydratase, uroporphyrinogen I synthetase, ferrochelatase) was also found (at
24 h) and the total porphyrin content of kidney (at 24 h) was markedly decreased
(117).
Effects on drug metabolism was shown in a study with male Sprague-Dawley
rats (51). The intraperitoneal injection of platinum(IV) chloride for two consecutive
days, at a dose of 18.9 mg/kg bw/day (56 mmoles/kg bw/day; 10.9 mg Pt/kg
bw/day) increased hexobarbital-induced sleeping time by approximately 50%
(p<0.05) and significantly decreased some parameters of drug metabolism mea-
sured in hepatic microsomes (decrease in cytochrome P450 and cytochrome b5).
A small decrease in the parameters of drug metabolism (significant decrease in
aminopyrine demethylase) and a small increase in sleeping-time was noted already
at a concentration of 4.7 mg/kg bw/day (14 mmoles/kg bw/day; 2.7 mg Pt/kg
bw/day). When soluble platinum salts (platinum(IV) chloride and platinum(IV)
sulphate) were administered in the diet or via drinking fluid for 1, 4 or 13 weeks
there was a general pattern concerning the parameters of drug metabolism: after
1 week of administration there was a decrease (or no alterations) in these para-
meters, while there was an increase (or no alterations) after 4 or 13 weeks. For
example treatment for 1 week with platinum(IV) sulphate at a concentration of
750 mg/L drinking fluid (1.6 mmol/L about 60 mg Pt/kg bw/day) caused a
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decreased activity (p<0.05) of aniline hydroxylase, while significant increases in
aniline hydroxylase or cytochrome b5 were observed when platinum(IV) chloride
was administered for 4 weeks at a dose level of 4.5 g/kg diet (13.2 mmol/kg diet)
corresponding to about 230 mg Pt/kg bw/day (total dose 1.58 g Pt /rat) or for
13 weeks at a dose level of 0.2 g/L (0.54 mmol/L; total dose 1.4 g Pt/rat or about
16 mg Pt/rat/day). Platinum(IV) oxide had marginal effects on the measured
parameters even at a dose level of 6.8 g/kg diet (29.8 mmol/kg diet; 4.9 g Pt/rat
during the 4 week treatment), which would correspond to about 700 mg Pt/kg
bw/day (50, 51).
Inhibition of DNA synthesis as measured by the incorporation of radioactive
thymidine, consistent with an inhibition of DNA polymerase according to the
authors, also was found in one study in male Sprague-Dawley rat with platinum(IV)
chloride (36). Thymidine incorporation in the spleen was reduced by one third at
intraperitoneal injection of a dose of 4.7 mg/kg bw (14 mmol/kg bw; corresponding
to 2.8 mg Pt/kg bw), while a decrease in thymidine incorporation in other tissues
(kidney, liver, testis) was found at higher dose levels.
11. Observations in man
11.1. Effects of single exposure
There are few reports of acute poisoning after exposure to platinum/platinum com-
pounds in man. Hardman and Wright 1896 (44) reported the death of a child aged
7 months who died five hours after the accidental administration of 8 gram of potas-
sium tetrachloroplatinate(II). A non-fatal case of platinum poisoning after oral
ingestion also has been described. A 31 year-old man ingested 600 mg of potassium
tetrachloroplatinate(II) suspended in a 10 ml solution in a suicide attempt. After 12
hours he complained of nausea, vomiting, diarrhea, and leg cramps. Subsequent
medical examination revealed acute renal failure with little urine output, mild hepa-
titis, fever, gastroenteritis, mild metabolic acidosis, leukocytosis, and eosinophilia.
The initial serum platinum concentration was 245 mg/dl and his spot urine platinum
concentration was 4200 mg/L. All symptoms and signs of toxicity resolved within
six days (180).
11.2. Effects of repeated exposure
Occupational exposure to platinum salts is a well-known cause of respiratory
allergic manifestations and skin reactions (20, 54, 124, 135). The symptoms
include lacrimation with burning and itching of the eyes, irritation of the upper
respiratory tract, running of the nose, sneezing, coughing, tightness of the chest,
wheezing and shortness of breath, as well as angioedema, urticarial and eczematous
skin lesions, usually on exposed areas (27, 59, 69, 87, 120, 131). However, true
allergic contact dermatitis from exposure to platinum compounds is rare and the
dermatitis occasionally seen sometimes may be of a primary irritant nature e.g.
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following exposure to strong acids and alkalis (20, 35, 58, 64, 84, 147). The
compounds mainly responsible for sensitisation are hexachloroplatinic(IV) acid and
chlorinated salts such as ammonium hexachloroplatinate(IV), ammonium tetra-
chloroplatinate(II), potassium hexachloroplatinate(IV), potassium tetrachloro-
platinat(II) and sodium hexachloroplatinate(IV)) (20, 38, 59, 87, 120, 124, 127,
135). Metallic platinum is not associated with hypersensitivity, although a single
case of dermatitis due to a platinum ring has been reported (147).
The latency period from the first exposure to platinum compounds to the occur-
rence of the first symptoms of a hypersensitivity disease varies between one week
and more than 20 years, but sensitisation usually develops within a few months to a
few years (31, 58, 94, 95, 119, 120, 125). The symptoms tend to become worse
upon continued exposure and sensitised individuals usually are never asymptomatic
in a platinum-containing atmosphere (38, 59, 93, 120, 131). When the subjects are
removed the symptoms generally disappear, but there are descriptions of workers
with a delayed response and nocturnal asthma, who have continued to experience
symptoms for a few weeks after removal (84, 131). Furthermore, a nonspecific
airway hyperreactivity may persist (7, 23, 93).
The particular effects attributable to platinum salts were first noted by Karasek
and Karasek (1911; cited in 58, 64) who examined workers in 40 photographic stu-
dios in Chicago and found eight persons who complained of irritation of the nose
and throat with accompanying sneeezing and coughing. Bronchial irritation with
difficulties in breathing was so severe in some cases that they were unable to use
paper treated with potassium chloroplatinate. Dermatitic skin lesions were also no-
ted during this study. Since then there have been numerous case reports relating
e.g. rhinitis, conjunctivitis, cough, asthma and urticaria to exposure of hexachloro-
platinic acid/complex salts of platinum in industry (mainly in workers and chemists
engaged in the refining of platinum), but no air concentrations are given in the stu-
dies (38, 64, 69, 81, 83, 87, 97, 120, 142, 167, 185).
The first occupational survey of platinum refinery workers, where measurements
of the platinum content of the air were made, was published in 1945 by Hunter et al
(59). They investigated all the workers in four British refineries and in some cases
attempted to test skin sensitivity (intradermally). Analysis of the symptoms showed
that 13 men had skin lesions: urticaria or scaly erythematous dermatitis of hands,
forearms and sometimes also face and neck. It was also stated that out of 91 men in
contact with the complex salts of platinum, 52 (57%) had the asthmatic syndrome to
some degree (suffered from sneezing, running of the nose, tightness of the chest,
shortness of breath, cyanosis, wheezing and cough), when they were in the factory
and for about one hour after they had left. Often these men also woke up early in the
morning with a bout of coughing. The incidence of asthma was highest in those in
contact with the complex salts in their dry form, but did occur also in those engaged
on certain parts of the wet processes, where droplets of the complex salts were pre-
sent in the atmosphere. The platinum content of the refinery atmosphere was esti-
mated at various points and during various operations with figures ranging from 0.9
mg/m3 to 1700 mg/m3 (table 7). In one of the platinum refineries, where the concent-
ration of platinum in the air was 0.9-3.2 mg/m3, 5 out of 7 workers said they experi-
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enced sneezing and running of the nose for a short duration, when they were in
contact with the complex salts of platinum for a few minutes at a time. No instances
of asthma was apparent in the workers exposed to metallic platinum dust only, in
any of the factories, despite that the sieving of spongy platinum produced a high
concentration of platinum in the atmosphere (400 to 960 mg/m3).
In some other early studies in refinery workers exposed to platinum salts the
occurrence of symptoms has been even higher (Table 13). In a five-year study of
employees in a platinum refinery in the USA all workers exhibited some degree of
inflammatory changes in the conjunctivae and the mucous membranes of the upper
respiratory tract, while 60% (12/20) were symptomatic (include e.g. burning and
itching of eyes, tightness in throat and chest, dry cough, asthma, itching of skin,
dermatitis). Nineteen of the men were also skin tested (scratch test) and 8 of these
had a positive skin test (131). In a French study (120) the prevalence of respiratory
and/or cutaneous manifestations was 69% (35/51) and the symptoms occurred
mostly at night and in accession to work. In two German studies work-related
symptoms such as sneezing, coughing, asthma, urticaria and eczema were found in
73% (8/11; 4 workers with symptoms had been removed and were not included)
and 88% (14/16) (89, 138). However, skin tests were not generally performed in
two of the three latter studies (89, 120). In the third study (138) about 80% of the
refinery workers showed positive patch tests, but the concentrations of the test
solutions (1% sodium hexachloroplatinate(IV) and 0.67% ammonium hexachloro-
platinate(IV)) were considered by the author as too high. No relevant measurements
of the content of platinum in the air were done in any of the studies (89, 120, 131,
138). In a report from 1975 (45) it was stated, that nasal ulceration was found in 8
of 16 workers (had proceeded to perforation of the septum in one case) exposed to
ruthenium and platinum salts during surface coating of anodes (include heating to
400-600°C) and that one other worker had suffered from a severe asthmatic attack.
The case of asthma was attributed to exposure to platinum salts, but because of the
absence of reports of nasal ulceration with platinum salts it was considered by the
author that the nasal ulceration and perforation described were due to ruthenium
salts rather than platinum salts. No exposure data were given in this study.
In a more recent Chinese study (149) the prevalence of allergic/irritative symptoms
was reported to be very high. For example skin lesions (characterized as pruritus
with face rashes) and/or mucosa irritation (running of the nose, sneezing, irritant
pain and running of the eyes) were found in 20 of the 23 examined workers, but the
total number of workers exhibiting symptoms was not given. Skin patch test with
sodium chloroplatinate was positive in nine cases, who accepted a 0.0075% test
solution. Air samples taken at various points of the refinery showed that the
workers were exposed to extremely high levels of dust or spray of complex plati-
num salts (5-80 mg/m3; at most points <10 mg/m3), but no close relationship
between the air levels and the incidence of symptoms was found. However, none of
these symptoms occurred in the workers exposed only to metallic platinum dust or
spray.   
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In a historical prospective cohort study (170) 91 workers (57 smokers) in a UK
platinum refinery who started work in 1973 - 1974 was followed up until 1980.
Forty-nine/ninety-one (54%) reported respiratory symptoms and 22 of those deve-
loped a positive skin prick test result to platinum salts. Smokers were found to have
an increased risk of sensitisation by platinum salts: smoking was the single most
important predictor of a positive skin test result to platinum salts (the risk was 4-5
times that in non-smokers) and consumption of cigarettes was the single most
important predictor of symptoms (the risk was about twofold greater). The risk
from atopy was smaller than that for smoking and was not significant after taking
account of smoking. One third of the workers were considered as atopics, but it
was stated, that people with a history of allergy were not employed in the refinery.
In an earlier abstract, a preliminary study of the 1973-1974 cohort was presented
(31). The results showed that 35/86 (41%) developed disease and all cases appeared
within two years of starting exposure. Of the 35 subjects affected, 24 developed
positive skin prick tests to platinum salts, while there were no positive reactions in
those unaffected (31). The air level of platinum was not given in any of the referen-
ces (31, 170).
In a large scale refinery survey published in 1986, 306 South African platinum
refinery workers accepted for employment on grounds of absence of evidence of
atopy were investigated. Thirty-eight (12.4%) had a positive skin prick test to plati-
num halide salts (107), but there were no data on number of workers with platinum
allergy related symptoms or air levels of platinum.
The prevalence of bronchial asthma and dermatitis was measured in a group of 16
Japanese workers engaged in the manufacture of platinum-coated oxygen sensors
(148 cited in 56). Measurements of the concentrations of Pt in the air ranged from
0.14 to 1.83 mg/m3 (48-hour averages of 0.46 and 1.1 mg/m3), but the work was
said to involve intermittent exposures to concentrations of ammonium hexachloro-
platinate(IV) higher than those in the workplace as a whole (e.g. during cleaning of
sensors). Results showed that 2/16 (12.5%) workers had severe work-related bron-
chial asthma and gave positive reactions on topical challenge with 1% hexachloro-
platinic(IV) acid solution. Among the remaining workers 11/14 showed contact
dermatitis, 6/14 showed pharyngeal irritation and 2/14 was said to suffer from nasal
obstruction, sneezing and coughing. Seven of the workers gave positive reactions
on topical challenge with 1% hexachloroplatinic(IV) acid. It was also stated that
pulmonary function tests and haematological measurements showed no abnormali-
ties. The prevalence of contact dermatitis in the study is very high and might point
to exposure to other compounds as well.
In a large investigation in the USA (7, 14, 23), 107 (87%) of 123 available cur-
rent workers and 29 former workers (suspected platinum salts allergy stated as the
reason for termination) in a plant, that reclaimed platinum and other precious metals
from scrap metals and consumed catalysts in 1981, were investigated. 65% of the
current and 97% of the terminated workers were smokers/ex-smokers. Rhinitis was
noted in 44% current and 34% terminated workers, asthma was reported in 29%
and 48%, respectively and a positive cold air challenge was found in 11% current
and 30% terminated workers. Positive platinum skin prick reaction was obtained in
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14% of current and 28% of terminated workers and the reactions in the current
workers mostly occurred at concentrations ranging between 10-6-10-3 g/ml, while
the terminated workers showed reactions at lower concentrations (10-9-10-6 g/ml)
(23). Sensitisation to platinum salts occurred among workers in all areas of the faci-
lity except the administrative offices. Platinum salts sensitivity generally varied di-
rectly with the environmental air concentrations of platinum salts in the employees«
present work areas and the risk of demonstrating platinum salts skin test reactivity
was calculated by the authors to increase 13% per 1 mg/m3 increment in work area
air concentration of platinum salts (p<0.01) (7). A positive skin prick test (platinum
salts) was found for 67% of the workers (2/3) in the tray room, where the mean air
concentration was 27.1 mg/m3, but only for 14% (2/14) of the employees in other
areas of the refinery (mean air concentration 10.7 mg/m3). 11% (2/19) of the wor-
kers in the analytical laboratories, where the mean air concentration was 0.4 mg/m3
(and the air measurements of platinum salts never exceeded 2.0 mg/m3) showed a
positive skin prick test. No correlation between air levels and symptoms was pre-
sented, but skin test reactivity to platinum salts was significantly associated with
increased prevalences of rhinitis symptoms, asthma symptoms, reported dermatitis
and a positive cold air challenge test, after controlling for aeroallergen sensitivity
and cigarette smoking status. A strong association between cigarette smoking and
the presence of a positive platinum skin test also was found, but platinum salts sen-
sitisation was not found to be associated with atopic tendency. An important obser-
vation was the high prevalence of symptoms consistent with allergic conditions
(e.g. positive cold air challenge, FEV1/FVC<70%) among former workers with a
persistent positive platinum skin prick test and with no apparent platinum salts ex-
posure during an average of five years since termination (7). Analysis of company
environmental monitoring data for 1977 to 1979, providing over 75 air measure-
ments of platinum salts, showed that the air levels in the refinery, recovery and wa-
rehouse areas  exceeded 2 mg/m3 (geometric means of 8-hour TWA levels) between
50 and 75% of the time (Table 7) (7, 23).
The occurrence of a persistent positive skin prick test as well as a nonspecific
airway hyperreactivity was also shown in a late German study on 24 refinery wor-
kers (15 smokers/ex-smokers) examined on two occasions. It was found, that most
individuals with an immediate-type asthma caused by platinum salts maintained a
nonspecific airway hyperreactivity for many months (1-77 months) after removal
from exposure. Although about one-third of the subjects ceased to have asthmatic
symptoms during the study period, there was no change in FEV1, or bronchial
hyperresponsiveness, nor was this the case with skin reactivity or bronchial respon-
siveness to platinum salt (skin prick tests with platinum salt became negative in
three subjects, but this was not accompanied by decreasing bronchial responsive-
ness to methacholine or platinum salt) (93). These results are in contrast to the
results found in an unpublished British study (Newman-Taylor, 1981 cited in 56).
In this study the prevalence of respiratory symptoms and skin sensitivity (skin prick
test) to ammonium hexachloroplatinate(IV) was determined in former workers of a
platinum refinery. The study population consisted of 109 individuals, 36 of whom
had ceased employment due to the development of platinum salt-related asthma
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(33%). Twenty-nine of the formerly Pt salt-sensitive and 41/73 of the non-
sensitised former workers participated in the follow-up study. Results showed no
statistically significant differences in pulmonary function tests (FEV1, FVC, cold air
reactivity) and no difference in the reporting of shortness of breath and chest tight-
ness between the formerly sensitised and non-sensitised subjects. The formerly
sensitised workers reported a greater prevalence of shortness of breath on exertion,
but this was judged to be of doubtful clinical significance. Twenty-seven of the 29
Pt salt-sensitive individuals had shown positive skin prick test at the time of leaving
employment, but only one worker still showed positive results at follow-up.
Today, when the air level of soluble platinum salts in industry generally is much
lower than some decades ago, platinum sensitivity is expected to be rare. However,
the above mentioned recent German study (93) indicates that this is not always the
case. Two other German studies (21, 95) support this finding. In one study (21) all
65 workers of the platinum-processing departments of a chemical plant were inves-
tigated with regard to the prevalence to allergic respiratory tract diseases. The mean
duration of exposure to platinum was 8.9 years (range 1-40 years). The occurrence
of conjunctivitis, rhinitis, coughing, expectoration or dyspnea related to work was
reported by 15 subjects (23%) and these symptoms were found more frequently in
the staff with high platinum exposure than in persons with moderate of low expo-
sure (p<0.01). Fifty-two per cent of the workers in this group suffered from work-
related symptoms, compared to 4% and 14% in the other two groups. The same
symptoms without a strict relation to the workplace were reported by 10 workers.
The group of workers with work-related symptoms showed normal lung function
before the beginning of the shift on Monday morning. In the course of the Monday
shift and the working week, there was a small but significant (p<0.05) fall in FEV1
from 100.7% to 95.9% of the predicted values. The FEF25 flow values fell mar-
kedly from 95.1% to 73.4% (p<0.05), but the resistance remained unchanged. In
the group with symptoms not related to work no significant changes in lung
function were found. Sixty-four of the workers also were skin prick tested. A posi-
tive cutaneous reaction with K2PtCl6 was found in 12 employees (18.7%). A posi-
tive result was obtained significantly more frequently in the group with work-related
symptoms of respiratory allergy (9/14) than in the other groups (2/10; 1/40). On the
other hand the staff with work-related symptoms showed sensitisation to the general
environmental allergens more rarely than did the rest of the staff. The employees
had been subdivided into three groups on the basis of the level of platinum exposure
(relatively high exposure, moderate exposure, relatively low exposure), but the air
levels of platinum for the different groups were not stated. Two stationary air
monitorings of platinum salts in total dust in the separation shop in 1984 (each over
3.5 h) revealed an air concentration of <0.2 mg/m3 (detection limit) and in 1986
(over 2 h) showed concentrations of 0.08 and 0.1 mg/m3. Two personal air moni-
torings in filter press workers for 1 h in 1986 revealed platinum salt concentrations
in total dust of  <0.05 mg/m3 (detection limit). Furthermore, it was stated that the
German OEL (2.0 mg/m3) was maintained over the long term. Otherwise no expo-
sure data were presented in the study.
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In another study (94, 95) 24/27 subjects working in a platinum refinery and 6
former workers (two workers with recurrent sporadic platinum exposure; four wor-
kers with 7, 9, 45 and 96 months since cessation of exposure) were investigated.
Two of the current workers (8%) and all the former workers suffered from work-
related symptoms, that is conjunctivitis, rhinitis, asthma and/or cutaneous mani-
festations (occupational exposure time for the group 8-60 months). Nine refinery
workers (occupational exposure time 0.5-306 months) had symptoms that could not
be clearly classified as work-related, but one worker from this group developed
work-related asthma five months after the study. Twenty-six of the 30 workers
allowed skin prick test and 10 of these had positive reactions: all workers from the
group with work-related symptoms (except one worker who did not allow skin
prick test) and three workers from the group with doubtful work-related symptoms
(including the worker who developed work-related asthma after the study).
Smoking was not found to increase the risk of developing platinum salt allergy, but
it was stated, that the symptomatic group had a higher exposure to platinum salts
than did workers of the other study groups. Platinum salt exposure in the different
working areas had been measured by the refinery and was said to be generally
below 0.08 mg/m3, but no expoure data were presented. Workers with work-related
symptoms were considered to have a higher exposure to platinum salts (score points
2.5) than did workers of the other study groups (score points 1.9 and 1.8), but the
exposure level was merely judged by the production manager (graded into 1-3 score
points). The drying process of the salts was designated as one of the most
dangerous processes (95). In a late report one of the authors (92) shortly presented
an investigation on 261 workers in a company producing catalysts, followed for at
least 2.5 years (1989-1992). The air levels were considered in general to be lower
than in platinum refineries, but no data on the measurements were given. It was
found that four workers suffered from platinum salt allergy at the first investigation
and four other workers developed the disease later (totally 3%). No cases of allergy
were found in areas where the exposure level of soluble platinum compounds were
below 0.01 mg/m3. However, the short duration of the study and the lack of details
concerning the number of employees exposed to different concentrations of
platinum salts should be noted.
In a pilot study (173), 21 men exposed to platinum metal dust for 6 weeks to
12 months during work with car catalysts (including recycling) and mechanical
treatment of platinum in a workshop was examined to detect signs of platinum
allergy. No data supporting the occurrence of platinum sensitivity was found, but
no details were given in the study. The air levels of platinum were 1.7-6.0 mg/m3
(around 6 mg/m3 during cutting and sawing).
11.3. Genotoxic effects
Data have not been found.
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Table 13. Prevalence of symptoms and positive skin tests in workers exposed to
soluble platinum salts
Total
workersa
Workers with
symptomsb
Prevalence of
symptoms (%)c
Air concentration
of platinum (mg/m3)
Ref
91 (16) 52 (4) 57 (25) 0.9-1700 59
20 (19)* 12 (8) 60 (42) nd 131
11 (nd) 8 (nd) 73 (nd) nd 89
16 (-) 14 (-) 88 (-) - 138
51 (nd) 35 (nd) 69 (nd) nd 120
91 (84)** 49 (22) 54 (26) nd 170
107 (107) 28***46****(15) 29*** 44**** (14) >2 7, 14, 23
24 (20) 2 (4) 8 (20) <0.08 94, 95
65 (64) 15 (12) 23 (19) <0.1, <2.0 21
a Values in parentheses are numbers of skin-tested workers.
b Values in parentheses are numbers of workers with a positive skin test.
c Values in parentheses give positive skin tests as a percentage of skin-tested workers.
*Findings made within five years.
**historical prospective cohort study
***asthma
****rhinitis
nd= not determined
11.4. Carcinogenic effects
Reports of cancer related to occupational exposure to platinum compounds have not
been found (34, 73, 108).
12. Dose-effect and dose-response relationships
There are no reports concerning other effects than allergy and irritation (skin and
mucous membranes) in humans occupationally exposed to soluble platinum salts
and data on the potential health effects in humans arising from exposure to platinum
metal or insoluble platinum compounds are completely lacking. Furthermore, there
are difficulties in establishing a dose-effect and dose-response relationship, since
there are wide variations in measured air levels of Pt (Table 7) and most workers
have changed their activities several times during their occupational exposure time.
However, in a few studies the exposure level to some extent has been related to the
prevalence of symptoms or positive skin prick test results and in one study a bron-
chial provocation test was used to correlate dose and effect. These studies are
briefly described below.
In a study on 107 platinum refinery workers (out of 123) the correlation between
air concentrations of platinum salts in the employees present work area and the pre-
valence of platinum salts skin sensitisation suggested an exposure-response rela-
tionship between the level of exposure and the prevalence of allergy (7, 14, 23).
The company«s environmental monitoring data for 1977 to 1979 providing over
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75 air measurements of platinum salt (geometric means of 8-hour time weighted
average air levels) were available for analysis and the risk of demonstrating
platinum salts skin test reactivity was calculated by the authors to increase 13% per
1 mg/m3 increment in work area air concentration of platinum salts (p<0.01). A
positive skin prick test (platinum salts) was found for 67% of the workers (2/3) in
one part (tray room) of the refinery, where the mean air concentration was
27.1 mg/m3. A positive skin prick test was also found for 14% (2/14) of the
employees in other areas of the refinery where the mean air concentration was
10.7 mg/m3. None of the office workers (0/15) was sensitive to platinum salts,
whereas 11% (2/19) of the workers in the analytical laboratories showed a positive
skin prick test. The mean air concentration of platinum in the air conditioning unit
(supplying air to the administrative offices of the facility) and in the analytical labo-
ratories were 0.6 mg/m3 and 0.4 mg/m3, respectively. The air measurements of
platinum salts in these areas never exceeded 2.0 mg/m3. No correlation between air
levels and symptoms was presented, but platinum salt sensitisation was signifi-
cantly associated with increased prevalences e.g. of rhinitis symptoms, asthma
symptoms and reported dermatitis.
The prevalence of allergic respiratory tract diseases in all 65 employees of the
platinum-processing departments of a German chemical plant was reported in
another study (21). It was found that 15/65 (23%) of the workers suffered from
work-related symptoms of respiratory allergy and 12/64 (19%) had a positive skin
prick test to platinum salts. Work-related symptoms were significantly more
frequent in the staff with high platinum exposure than in persons with moderate or
low exposure (p<0.01). Thus, 52% of the workers in this group suffered from
work-related symptoms, compared to 4% and 14% in the other two groups. A
positive skin prick test was also obtained significantly more frequent in workers
with work-related symptoms of respiratory allergy, than in other workers. The
employees had been subdivided into three groups on the basis of the level of plati-
num exposure (relatively high exposure, moderate exposure, relatively low expo-
sure), but the air levels of platinum for the different groups were not stated. How-
ever, two stationary air monitorings in total dust in the separation shop in 1986 over
2 hours showed concentrations of platinum salts of 0.08 and 0.1 mg/m3, and two
personal air monitorings in filter press workers for 1 hour in 1986 revealed plati-
num salt concentrations in total dust of <0.05 mg/m3 (detection limit). It was also
stated that 2.0 mg/m3 was maintained in the plant over the long term. Otherwise no
exposure data were presented in the study.
In a study on 24 subjects (24/27 participated) working in another German plati-
num refinery the prevalence of clearly work-related asthmatic/upper respiratory tract
symptoms was only 2/24 (8%), but one worker with doubtful work-related symp-
toms (rhinitis and a positive skin prick test with PtCl6
2-) developed work-related
asthma five months after the study and further two workers belonging to the group
with doubtful work-related symptoms showed a positive cutaneous reaction with
(PtCl6)
2- (20 current workers were skin prick tested and 20% showed a positive
test). The only symptom they experienced was rhinitis which occurred regularly
after exposure, but also at home, and did not disappear during weekends (94, 95).
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Workers with work-related symptoms were considered to have a higher exposure to
platinum salts (score points 2.5) than did workers of the other study groups (score
points 1.9 and 1.8), but the exposure level was merely judged by the production
manager (graded into 1-3 score points) and air levels of Pt were not given for any of
the groups. Platinum salt exposure in the different working areas had been measu-
red by the refinery and was stated to be generally below 0.08 mg/m3 (no exposure
data were presented). In a later report one of the authors (92) shortly presented an
investigation on 261 workers in a company producing catalysts (1989-1992). The
air levels were considered as lower in general, than in platinum refineries, but data
on the measurements were not given. It was found that about 3% of the workers
developed platinum salt allergy, but no cases of allergy were found in areas where
the exposure level of soluble platinum compounds were below 0.01 mg/m3. The
short duration of the study and the lack of details concerning the number of
employees exposed to different concentrations of platinum salts preclude definite
conclusions on the risk of developing sensitisation reactions.
When bronchial provocation test with platinum salt was performed on 27/35 for-
mer platinum refinery workers with work related symptoms, 22 of these showed a
fall of 50% or more in specific airway conductance, whereas none of the controls
showed any reaction (94). It was calculated by the authors, that at the occupational
exposure limit (OEL) value of 2 mg/m3 workers inhale about  2.0x10-8 g/minute or
0.5x10-10 mol/minute and that this corresponds to the provocation dose causing
50% fall in specific airway conductance (PD50sGaw) in bronchial provocation tests
with platinum salt; however, details of how the calculations are made are lacking.
The authors concluded, that in a number of countries legal OEL values for occupa-
tional platinum salt exposure bear risks for those workers who are sensitised to
platinum salt.
There are few inhalation studies of platinum compounds in animals. In one study
(17) signs of bronchial hyperreactivity (serial bronchoprovocation challenges with
increasing concentrations of the platinum salt) was found in monkeys after inter-
mittent exposure for 12 weeks to sodium hexachloroplatinate(IV) at the exposure
level of 200 mg Pt/m3, but not at the exposure level 2000 mg Pt/m3. (Significant
impairments in pulmonary function was also shown in control animals after chal-
lenge with the highest concentration of the platinum salt). However, in a later study
(16) exposure to about 200 mg/m3 ammonium hexachloroplatinate(IV) had no signi-
ficant effects on postexposure Pt or methacholine reactivity in monkeys. Further-
more, there were no overt ill effects or significant differences in body weights, but
the study was designed to detect differences in immunologic parameters and effects
in the airways. There are other studies in animals in which platinum compounds are
administered in other ways. The results of some of these studies are summarised in
Table 14.
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Table 14. Some dose-effect data for animals exposed to soluble platinum compounds
Exposure Species Effect Ref
H2PtCl6: 40-50 mg/kg bw
(15-19 mg Pt/kg bw*) ip, single dose
male rat (F344
Fischer CDF)
LD50, renal failure, histopatol
lesions in kidney, thymus
171
PtCl4: 27 mg/kg bw (0.08 mmol/kg
bw; 15.6 mg Pt/kg bw) intra-
testicular, single dose
rat (albino) decreased testis weight, testi-
cular necrosis with destruction
of spermatozoa
70
Pt(SO4)2x4H2O: 750 mg/L drinking-
water for 8 days; total intake 60 mg
Pt/rat (about 140 mg/kg bw/day or
59 mg Pt/kg bw/day)
male rat
(Sprague-
Dawley)
reduced weight gain, decreased
activity of aniline hydroxylase
50, 51
PtCl4: 550 mg/L drinking-water for
29 days; total intake 250 mg Pt/rat
(about 74 mg/kg bw/day or 43 mg
Pt/kg bw/day)
male rat
(Sprague-
Dawley)
increase in relative kidney
weight, reduced weight gain
50
PtCl4: 50 ppm Pt in the diet for 4
weeks; total intake 21 mg Pt/rat
(about 8.6 mg/kg bw/day or 5 mg
Pt/kg bw/day)
male rat
(Sprague-
Dawley)
sign increase in plasma creati-
nine; decrease in erythrocyt
count, haematocrit
130
PtCl4: 0.9 mg/kg bw/day (0.08
mmol/kg bw tot dose; 0.52 mg Pt
/kg bw/day) sc, 30 days
mouse (Swiss) decreased testis weight, sper-
matogenic arrest
70
*molecular weight counted on the hexahydrate
13. Previous evaluations by (inter)national bodies
Recently, the UK Health and Safety Executive (HSE) has published a criteria
document on platinum metal and soluble platinum salts. Their conlusions were: A
number of studies have provided clear evidence that exposure to the platinum chlo-
ride salts leads to skin and respiratory hypersensitivity in humans. The available
data do not allow conclusions to be drawn as to whether or not a threshold for
respiratory sensitisation exists. No data are available on the potential health effects
in humans arising from exposure to platinum metal or insoluble platinum salts. The
lack of any documented cases of allergy suggests that it is unlikely that platinum
metal is capable of eliciting the skin and respiratory health effects associated with
soluble platinum salts. A summary of the animal studies show, that some platinum
salts may produce irritation of skin, eye and respiratory tract. The genotoxic poten-
tial of platinum salts has not been systematically investigated, but from the limited
data available it appears that some soluble platinum salts are mutagenic in vitro,
although this potential has not been demonstrated in vivo.
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The conclusions of the International Programme on Chemical Safety (IPCS) in
1991 on health effects of platinum and platinum compounds were: By far the most
significant health effect from exposure to soluble platinum salts is sensitisation.
Some halogenated platinum salts are highly allergenic in humans. There is no evi-
dence for sensitisation from metallic platinum, except for one unsubstantiated case
of contact dermatitis. The present occupational exposure limit (2 mg/m3) might not
be sufficient to prevent platinum salt hypersensitisation, although it is difficult to
reach a firm conclusion because of the lack of adequate data. To minimize the risk,
workplace exposure should be as low as practicable. No data are available to assess
the carcinogenic risk of platinum or its salts to humans.
14. Evaluation of human health risks
14.1. Groups at extra risk
There are only limited data to quantify workplace exposure. However, occupational
exposure to the soluble, halogenated platinum compounds, known to be responsible
for sensitisation, is mainly found during primary refining of platinum, during cata-
lyst manufacture and when platinum is reclaimed from scrap metal and expended
catalysts.
Smokers seem to be more susceptible to the sensitising effects of platinum salts,
whereas this cannot be clearly judged for the atopic status (7, 23, 170; Linnett,
1985, cited in 84). A correlation between atopy and allergy for platinum compounds
is indicated in some early studies (108), but there might be confounding factors e.g.
smoking. In more recent studies atopy has not been correlated to platinum sensi-
tivity. This may be due to pre-employment screening and to small study populations
(7, 21, 58, 170). However, preemployment screening and exclusion of atopics will
never solve the problem since allergy to platinum salts also occurs to a large extent
in nonatopics. Furthermore, atopy is very common, and decisions made because of
atopy probably affect about one third of the working population. Thus, prevention
should focus on environmental control (112, 169).
14.2. Assessment of health risks
The most significant health risks from occupational exposure to soluble platinum
salts are respiratory sensitisation and skin effects. There is scarcely any information
of the health effects in humans arising from exposure to platinum metal, but it is
unlikely that platinum metal is capable of eliciting the allergic reactions associated
with some soluble platinum salts, since no cases of respiratory health effects attri-
buted to platinum metal are known and only one single case of contact dermatitis
has been reported.
The prevalence of respiratory/cutaneous symptoms among refinery workers
exposed to platinum salts has been very high - frequently over 50% - and some-
times the disease has developed very rapidly (59, 89, 120, 131, 138, 170). The
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exposure conditions have improved during the last decades and the prevalence of
work-related symptoms in some later studies was lower (8-23%), but still positive
skin prick tests to platinum salts were obtained in about 20% of the tested workers
(21, 94, 95). A correlation between the prevalence of work-related symptoms and
exposure level of platinum salts has been stated in a few studies (21, 94, 95).
However, few exposure data are presented and the importance of peak exposures of
short duration for sensitisation cannot be evaluated on the basis of existing data. In
one study (7, 14, 23) the risk of demonstrating platinum salts skin test reactivity
(skin prick test) was calculated by the authors to increase 13% per 1 mg/m3 incre-
ment in work area air concentration of platinum salts.
In many cases the respiratory/cutaneous reactions following exposure to platinum
salts has been shown to be IgE-mediated. Specific sensitisation has been demon-
strated in skin prick tests with a range of 12-26% in later studies (7, 14, 21, 23, 94,
95, 107, 170). Indications of the potency of the soluble halogenated salts of plati-
num are, that with a typical delivery of 3x10-6 ml solution into the epidermis, a salt
concentration of 10-9 g/ml (according to the authors) is sufficient to elicit a positive
reaction in sensitised skin (27, 108, 124) and the fact that concentrations of 1 mg/ml
potassium hexachloroplatinate(IV) intradermally have caused anaphylactic reactions
(27, 38). Furthermore, if the workers are exposed to low levels of other irritant or
toxic gases and fumes as well (e.g. chlorine, hydrogen chloride, nitric acid and
ammonia), this may possibly potentiate the effects of platinum salt exposure (7, 13,
16, 84). However, respiratory and cutaneous symptoms are not always due to
specific sensitisation and thus non-allergic mechanisms and irritative effects also
should be born in mind (152). It has been postulated that the dermatitis occasionally
seen among refinery workers sometimes are of a primary irritant nature e.g. fol-
lowing exposure to strong acids and alkalis (20, 35, 58, 64, 84, 147). In addition
to the platinum-specific respiratory reactions, an unspecific bronchial hyperreacti-
vity that may persist for years after exposure has ceased has also been shown in
some studies (7, 23, 93).
There are no reports of other effects of platinum compounds than allergy/irritation
of the respiratory tract and skin after occupational exposure. Nausea, vomiting,
diarrhea, and leg cramps was described in one case after ingestion of 600 mg of
potassium tetrachloroplatinate(II). Subsequent medical examination revealed acute
renal failure, mild hepatitis, mild metabolic acidosis and gastroenteritis (180). In
animal experiments some platinum salts have been shown to produce irritation of
skin, eye and respiratory tract. Effects e.g. on kidney, testis, blood and thymus
have been observed after peroral, subcutaneous or intraperitoneal administration of
hexachloroplatinic acid/soluble platinum salts, at dose levels corresponding to air
levels much higher than present work place exposure levels. Many platinum
salts/complexes have been shown to be mutagenic in vitro, but the genotoxicity of
platinum compounds (except platinum containing drugs) is not very well investi-
gated and it is not possible from the available studies to draw firm conclusions
regarding the risk from exposure to platinum compounds in the work environment.
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14.3 Scientific basis for an occupational exposure limit
In the occupational setting where inhalation exposure is dominating, the critical
effects of soluble platinum salts are those related to the respiratory tract, whereas no
critical effects can be established for platinum metal or insoluble platinum com-
pounds. Some of the halogenated complex salts of platinum are potent respiratory
sensitisers in human and only small amounts of the compounds might be needed for
induction of sensitivity, but the amounts required to elicit reactions are far lower.
Thus even very low OEL values may be inadequate for prevention of reactions in
already sensitised subjects and there are clear indications that 2 mg/m3 - the legal
occupational exposure limit used in a number of countries - is not sufficiently low to
protect the workers from elicitation of allergic symptoms (7, 14, 21, 23, 92, 95). It
is difficult to establish a LOAEL, because few exposure data are available and are
poorly reported (see Section 12); however, a LOAEL may be as low as 0.08-0.1
mg/m3 (21, 95). Existing data on exposure-response relationships do not allow the
identification of a NOAEL for soluble platinum salts. It should be noted, that peak
exposures of short duration occur, which may be of importance for the induction of
sensitivity.
15. Research needs
One problem in assessing the risk of humans from exposure to platinum is the ana-
lytical problems and the definition of reference values (baseline concentrations) in
blood, urine and tissues. The absence of adequate reference values makes it difficult
to establish relationships between element concentrations, toxic effects and air
levels.
There is also a need for more information on possible genotoxic effects. The anti-
neoplastic agent cisplatin and some analogues bind to DNA and are mutagenic. A
few antitumor cis-platinum(II) coordination complexes (including cisplatin) also
have been shown to be carcinogenic in animal studies. The mutagenicity and carci-
nogenicity of other platinum compounds is less well investigated, but due to diffe-
rences in chemical reactivity (lability of ligands, number of active sites etc) it is
reasonable to expect that not all forms of platinum pose this hazard. However,
many platinum salts/complexes have been shown to be mutagenic in vitro and thus
further investigations e.g. animal studies, cytogenetic tests and well performed
epidemiological studies would be of interest.
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16. Summary
Lindell B. DECOS and NEG Basis for an Occupational Standard. Platinum. Arbete
och Hlsa 1997;14:1-65.
The most significant health risk from occupational exposure to soluble platinum
compounds is sensitisation of the airways. It is during the production and handling
of hexachloroplatinic acid and certain complex halogenated salts of platinum,
allergic symptoms involving the respiratory tract and the skin have occurred.
Smokers seem to be more susceptible to the sensitising effects of platinum salts,
whereas this cannot be clearly judged for the atopic status. Elicitation of allergic
symptoms occur at Pt air levels below 2 ug/m3, possibly at Pt levels as low as about
0.1 ug/m3. Platinum metal is not associated with allergy. There are no reports of
other effects of platinum compounds than allergy/irritation at occupational exposure.
Many platinum salts/complexes are mutagenic in vitro, but it is not possible from
the available studies to draw conclusions regarding the genotoxic risk in the work
environment.
Keywords: allergy, asthma, health effects, irritation, occupational exposure limit,
platinum, platinum salts, refinery, review, rhinitis, risk assessment
17. Summary in Swedish
Lindell B. DECOS and NEG Basis for an Occupational Standard. Platinum. Arbete
och Hlsa 1997;14:1-65.
Den mest signifikanta hlsorisken vid yrkesmssig exponering fr lsliga platina-
freningar r sensibilisering av luftvgarna. Det r vid produktion och hantering av
hexakloroplatinasyra och vissa halogenerade platinakomplexsalter, som allergiska
symptom i luftvgar och hud har rapporterats. Rkare frefaller vara mer mottagliga
fr platinasalters sensibiliserande effekter, medan ett samband med atopi inte har
klarlagts. Allergiska symptom kan utlsas vid Pt lufthalter lgre n 2 ug/m3,
mjligen vid s lga halter som c:a 0.1 ug/m3. Platinametall har inte associerats med
allergi. Det finns inga rapporter angende andra effekter av platinafreningar vid
yrkesmssig exponering n allergi/irritation. Mnga platinasalter/komplex r
mutagena in vitro, men det r inte mjligt att dra slutsatser frn tillgngliga studier
angende genotoxisk risk i arbetsmiljn.
Nyckelord: allergi, astma, hygieniskt grnsvrde, hlsoeffekter, irritation, platina,
platinasalter, rinit, riskbedmning, smltverk, versikt
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Appendix 1a.
Permitted or recommended maximum levels of platinum (metal) dust in air
Country ppm mg/m3 Comments Year Ref.
Denmark 1 1994 1
Finland 1 1996 2
Germany - 1996 3
Iceland - 1989 4
Netherlands 1 1996 5
Norway - 1995 6
Sweden - 1996 7
USA (ACGIH) 1 1996 8
  (NIOSH) 1 1994 9
(OSHA) - 1994 9
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Appendix 1b.
Permitted or recommended maximum levels of soluble platinum salts (as Pt) in air
Country ppm mg/m3 Comments Year Ref.
Denmark     0.002 1994 1
Finland  0.002   1996 2
Germany 0.002 Chloroplatinum 1996 3
ceiling; S
Iceland - 1989 4
Netherlands 0.002 1996 5
Norway 0.002 1995 6
Sweden - 1996 7
USA (ACGIH) 0.002 1996 8
  (NIOSH) 0.002 1994 9
(OSHA) 0.002 1994 9
S = risk for sensitisation
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